

June 14, 2018

Siri & Glimstad LLP Aaron Siri Esq. 200 Park Ave 17th Floor New York, NY 10166

In reply refer to file: 2018-3994

Dear Mr. Siri,

This is in reply to your Freedom of Information Act (FOIA) request dated May 8, 2018 in which you requested "Documents sufficient to identify the ingredients of the 'placebo' in the prelicensure clinical trials identified in Section 6.1 of the package insert for RotaTeq." Your request was received in the Center for Biologics Evaluation and Research (CBER) on May 14, 2018.

In our telephone conversation on May 25, 2018 it was agreed that CBER would provide you with the cover page, relevant table of content pages, and the pages discussing the ingredients of the placebo from the 3 responsive clinical trial reports related to the trials discussed in section 6.1 of the product package insert.

Enclosed are the documents responsive to your clarified request.

We have withheld portions of pages under Exemption (b)(4), 5 U.S.C. § 522(b)(4). That exemption permits the withholding of trade secrets and commercial or financial information that was obtained from a person outside the government and that is privileged or confidential. The withholding of such information is permitted if disclosure is likely to cause substantial competitive harm to the person who submitted the information.

You have the right to appeal this determination. By filing an appeal, you preserve your rights under FOIA and give the agency a chance to review and reconsider your request and the agency's decision.

Your appeal must be mailed within 90 days from the date of this response to:

Ms. Catherine Teti Deputy Agency Chief FOIA Officer U.S. Department of Health and Human Services Office of the Assistant Secretary for Public Affairs Room 729H 200 Independence Avenue, S.W. Washington, DC 20201

Please clearly mark both the envelope and your letter "FDA Freedom of Information Act Appeal."

If you would like to discuss our response <u>before</u> filing an appeal to attempt to resolve your dispute without going through the appeals process, please contact:

Beth Brockner-Ryan, Branch Chief Center for Biologics Evaluation and Research (CBER) Access Litigation and Freedom of Information Branch U.S. Food and Drug Administration 10903 New Hampshire Avenue Building 71, Room 1114 Silver Spring, MD 20993-0002 Email:beth.brocknerryan@fda.hhs.gov Main Line 240-402-7800 FOI Line 240-402-8008

You also have the right to contact:

FDA FOIA Public Liaison Office of the Executive Secretariat 5630 Fishers Lane Room-1050 Rockville, MD 20857 Email: FDAFOIA@fda.hhs.gov

If you are unable to resolve your FOIA dispute through our FOIA Public Liaison, the Office of Government Information Services (OGIS), the Federal FOIA Ombudsman's office, offers mediation services to help resolve disputes between FOIA requesters and Federal agencies. The contact information for OGIS is:

Office of Government Information Services National Archives and Records Administration 8601 Adelphi Road–OGIS College Park, MD 20740-6001 Telephone: 202-741-5770 Toll-Free: 1-877-684-6448 E-mail: ogis@nara.gov Fax: 202-741-5769

The following may be included in a monthly invoice:

Search	0.75 Hour	@ \$46.00/hr	\$34.50
Review	4.25 Hours	@ \$46.00/hr	\$195.50

TOTAL

\$230.00

The above charges may not reflect final charges for this request. Please DO NOT send any payment until you receive an invoice from the Agency's Freedom of Information Staff (HFI-35).

If you have any questions or if we can be of further assistance, please let us know by referencing the above file number. You can contact John Matthew Hyder by phone at 240-402-8079 or by e-mail at John.Hyder@fda.hhs.gov.

Sincerely, Beth A. Brockner Ryan - Section 2010 101 1 - 1300032489 cm-Beth A Brockner Ryan

Beth Brockner Ryan Chief, Access Litigation and Freedom of Information Branch

Reference P006

MRL Clinical Study Report, Multicenter Study: Safety and Efficacy of Pentavalent (G1, G2, G3, G4, and P1) Human-Bovine Ressortant Rotavirus Vaccine in Healthy Infants (Protocol 006)

CLINICAL STUDY REPORT

Safety and Efficacy of Pentavalent (G1, G2, G3, G4, and P1) Human-Bovine Ressortant Rotavirus Vaccine in Healthy Infants

TABLE OF CONTENTS

				Application Starting Page
I.	SYI	NOPS	SIS	44
II.	CO	MPR	EHENSIVE STUDY SUMMARY	61
	1.	Intr	oduction	61
	2.	Eth	ics	67
		2.1	Ethics Review Committee/Independent Ethics Committee/Institutional Review Board	67
		2.2	Ethical Conduct of the Study	67
		2.3	Subject Information and Informed Consent Form	67
	3.	Inve	estigators and Study Administrative Structure	69
		3.1	Investigators	69
		3.2	Independent Committees for the Assessment of Safety	69
		3.3	Laboratories	70
		3.4	Contract Research Organizations	71
		3.5	Additional Vendors	73
		3.6	Authors of Clinical Study Report (CSR)	74
	4.	Stud	dy Hypotheses and Objectives	75
		4.1	Hypotheses	75
		Z	4.1.1 Primary	75
		Z	4.1.2 Secondary	75
		Z	4.1.3 Tertiary	76
		4.2	Objectives	77
		Z	4.2.1 Primary Objectives	77
		Z	4.2.2 Secondary Objectives	77

TABLE OF CONTENTS (CONT.)

				Application Starting Page
	4.2.3	Tertiary Objectives		78
5.	Investiga	ional Plan		79
	5.1 Ove	all Study Design and Plan: Description		79
	5.1.1	Description of Study Design		79
	5.1.2	Description of Study Cohorts		86
	5.2 Disc Con	ussion of Study Design, Including the Cl rol Groups	hoice of	97
	5.2.1	Efficacy		98
	5.2.2	Effectiveness of RotaTeq [™] in Improvin Outcomes	ig Health	99
	5.2.3	Immunogenicity		99
	5.2.4	Safety		100
	5.3 Sele	ction of Study Population		100
	5.3.1	Inclusion Criteria		101
	5.3.2	Exclusion Criteria		101
	5.3.3	Discontinuation of Subjects From Thera Study Observation	ıpy or	102
	5.4 Trea	tments		103
	5.4.1	Treatments Administered		103
	5.4	1.1 RotaTeq [™] Versus Placebo		103
	5.4	1.2 Concomitant Pediatric Vaccines		103
	5.4.2	Identity of Clinical Supplies		104
	5.4	2.1 RotaTeq [™] and Placebo		104
	5.4	2.2 Concomitant Pediatric Vaccines		107
	5.4	2.3 Development of Clinical Materials	L	109
	5.4.3	Method of Assigning Subjects to Treatm Groups	nent	112
	5.4.4	Selection of Doses in the Study and Tin Doses for Each Subject	ning of	113
	5.4.5	Study Blinding		114
	5.4.6	Prior and Concomitant Therapies		120

CSR SYNOPSIS (CONT.) Protocol 006

V260 Rotavirus

Rotavirus Vaccine, Live, Oral, Pentavalent

-3-

VA0016M001, V260 VA0016M002, V260 VA0016M003, V260 VA0016M004, V260 VA0017N001,V260 VA0017N002, V260 VA0017N003, V260 VA0021R001), when fully characterized, contained approximately (b) (4) mg of sucrose, approximately (b) (4) mg of sodium phosphate, approximately (b) (a) mg of tissue culture medium, and no greater than (b) mg of polysorbate-80, and human-bovine rotavirus reassortants G1, G2, G3, G4, and P1 with an aggregate potency ranging from $67.2x10^6$ to $124x10^6$ infectious units (IU)/dose in approximately 2 mL of buffer/stabilizer. Theoretical calculation of (b) (4) material (b) (4) was (a) mg/dose. Trace components of fetal bovine serum may have also been present. The stability of RotaTeqTM was assessed at predefined evaluation points throughout the study.

Placebo (Lot Numbers: PV260 VAO005A001, PV260 VAO006A001, PV260 VAO006A002, PV260 VAO006A003, PV260 VAO006A004, PV260 VAO009A001, PV260 VAO009A002, PV260 VAO009A003, PV260 VAO009A004, PV260 VAO009A005, PV260 VAO009A006, PV260 VAO009A007, PV260 VAO009A008, PV260 VAO009A009, PV260 VAO0015A001, PV260 VAO0015A002, PV260 VAO0015A003, PV260 VAO0015A004, PV260 VAO0015A005, PV260 VAO0015A007, PV260 VAO0015A004, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A007, PV260 VAO0015A004, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A007, PV260 VAO0015A004, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A007, PV260 VAO0015A004, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A005, PV260 VAO0015A007, PV260 VAO0015A005, PV260 VAO005A005, PV260 VAO005A05, PV260 VAO005A05, PV260 VAO005A05, PV260 VAO005A05, PV260 VAO05A05, PV260 VAO5A05, PV260 VAO5A5, PV260 VAO5A5, PV260 VAO5A5, PV260 VAO5A5, PV260 VA

polysorbate-80. (4)

For a subset of subjects in the United States (U.S. Concomitant Use Cohort), Merck also provided the licensed pediatric vaccines that were administered concomitantly (same day) with RotaTeqTM or placebo, which included COMVAXTM, INFANRIXTM, IPOLTM, and PREVNARTM. These vaccines were administered at a dose of 0.5 mL.

<u>COMVAX™</u> (Lot Number: 1076L) was supplied in 0.5-mL single dose vials. <u>INFANRIX™</u> (Lot Numbers: DTPA524A2, DTPA572A2, DTPA575A2) was supplied in 0.5-mL single-dose vials.

<u>IPOLTM</u> (Lot Numbers: T1153-2 and T1189-2) was supplied in prefilled syringes and/or multidose vials, 0.5-mL per dose.

<u>PREVNARTM</u> (Lot Numbers: 491-171 and 491-178) was supplied in 0.5-mL single-dose vials. PREVNARTM was in short supply over the course of the study. When not available for Merck to provide, the study sites were permitted to administer PREVNARTM from their supply. If PREVNARTM was provided locally by the physician, the single panel, open label was not used. The lot number and expiration date were to be recorded.

DIAGNOSIS/INCLUSION CRITERIA: Healthy infants, 6 through 12 weeks of age, who had no known history of congenital abdominal disorders, intussusception, or abdominal surgery; no known or suspected impairment of immunological function; no known hypersensitivity to any component of the rotavirus vaccine; no prior receipt of any rotavirus vaccine; no fever, with a rectal temperature ≥38.1°C (≥100.5°F) at the time of immunization; no history of known prior rotavirus disease, chronic diarrhea, or failure to thrive; no clinical evidence of active gastrointestinal illness. (Note that infants with gastroesophageal reflux disease [GERD] were permitted to participate in the study as long as the GERD was well controlled with or without medication.); no receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 2 weeks prior to vaccination; did not reside in a household with an immunocompromised person; no prior receipt of a blood transfusion or blood products, including immunoglobulins; no receipt of oral poliovirus vaccine (OPV) during the course of the study or within 42 days prior to the first dose of vaccine/placebo.

EVALUATION CRITERIA:

Efficacy: The case definition for rotavirus gastroenteritis required subjects to meet both of the following criteria: (1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and (2) rotavirus detected by enzyme immunoassay (EIA) in a stool specimen taken within 14 days after the onset of symptoms. All rotavirus-positive stools were evaluated for serotype identification by polymerase chain reaction (PCR). Only naturally-occurring rotavirus AGEs caused by the composite of the human rotavirus G-serotypes in the vaccine (G1, G2, G3, and G4) occurring

-26-

5.4.2 Identity of Clinical Supplies

5.4.2.1 RotaTeqTM and Placebo

Each dose of Rota TeqTM contained human-bovine rotavirus reassortants G1, G2, G3, G4, and P1 with an estimated final aggregate dose range of approximately 67.2 x 10⁶ to 124 x 10⁶ IU/dose in approximately 2.0 mL of buffer/stabilizer. The potencies of the individual human-bovine reassortants were determined via the Multivalent Quantitative Polymerase Chain Reaction Assay (M-QPA). A description of this assay can be found in Section II.11.12.1. The vaccine was a buffered, liquid product that was originally stored at 2° to 8°C¹. The formulation used in this study, when fully characterized, contained approximately (b) (4) mg of sucrose, approximately (b) (4) mg of sodium phosphate, approximately (b) (b) (c) mL of tissue culture medium, and no greater than (b) (4) mg of polysorbate 80. Theoretical calculation of (b) (4) material (b) (4) was mg/dose. Trace components of fetal bovine serum may have also been present. The stability of RotaTeqTM was assessed at predefined evaluation points throughout the study.

The placebo was approximately 2.0 mL per dose that contained approximately (b) (4) mg of sucrose, approximately $\binom{(0)}{(4)}$ ng of sodium citrate, approximately (b) (4) mg of sodium phosphate, and no greater than $\binom{(b)}{(4)}$ mg of polysorbate 80.

RotaTeq[™] or placebo was packaged in 2 different ways for this study including vials and dose packages. The dose packages consisted of labeled foil pouches containing oral dosing tubes. Initially, the clinical materials (RotaTeq[™] or placebo) were packaged in 6.0-mL labeled vials containing approximately 2.5 mL of product. Two (2) mL of RotaTeq[™] or placebo were drawn up from the vial using a syringe. The needle was removed from the syringe and the vaccine was dispensed orally to the infant. During the course of the study, 5.5-mL labeled oral dosing tubes containing approximately 2.16 mL of product and designed to deliver approximately 2.0 mL were introduced. These dosing tubes represent the final container for RotaTeq[™] intended for market. The study provided the opportunity to test the final oral dosing tubes in the clinic. The tubes had a twist-off cap. The cap was removed and the vaccine was delivered orally to the infant directly from the tube. Regardless of the container for clinical materials, approximately 2.0 mL of RotaTeq[™] or placebo was administered to all subjects under double-blinded conditions (see Section II.5.4.5).

CSR Investigational Plan_V260_006_P006 VERSION 30.3 APPROVED Restricted � Confidential – Limited Access 14-Mar-2005

At the time of the Protocol Amendment 006-01[3.3.2], (b) (4)

LIST OF APPENDICES (CONT.)

	Appendix	Application Starting Page
1.1.18	Velázquez FR, Matson DO, Calva JJ, Guerrero ML, Morrow AL, Carter-Campbell S. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996;335(14):1022-8.	1689
1.1.19	Santssham M, Moulton LH, Reid R, Croll J, Weatherbolt R, Ward R, et al. Efficacy and safety of high- dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997;131(4):632-8.	1696
1.1.20	Pittman M. The concept of pertussis as a toxin- mediated disease. Pediatr Infect Dis J 1984;3(5):467-86.	1703
1.1.21	Robbins JB, Pittman M, Trollfors B, Lagergard TA, Taranger J, Schneerson R. Primum non nocere: a pharmacologically inert pertussis toxoid alone should be the next pertussis vaccine. Pediatr Infect Dis J 1993;12(10):795-807.	1723
1.1.22	Trollfors B, Taranger J, Lagergård T, Lind L, Sundh V, Zackrisson G, et al. A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995;333:1045-50.	1736
1.1.23	Liese JG, Meschievitz CK, Harzer E, Froeschle J, Hosbach P, Hoppe JE, et al. Efficacy of a two- component acellular pertussis vaccine in infants. Pediatr Infect Dis J 1997;16(11):1038-44.	1742
1.1.24	Lynn F, Reed GF, Meade BD. Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to bordetella pertussis antigens. Clin Diagn Lab Immunol 1996;3(6):689-700.	1749
CATEGORY 2:	REPORTS	
2.1	MRL or Other Clinical Study Reports (Synopses)	
2.1.1	MRL Clinical Study Report (Synopsis): Safety, Tolerability, and Immunogenicity of Live Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine in Healthy Adults (Protocol 001).	1761
2.1.2	MRL Clinical Study Report (Synopsis), Multicenter Study: Safety, Immunogenicity, and Efficacy of a Live, Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine in Healthy Infants (Protocol 002).	1764

LIST OF APPENDICES (CONT.)

	Appendix	Application Starting Page
2.1.3	MRL Clinical Study Report (Synopsis), Multicenter Study: Safety, Immunogenicity, and Efficacy in Healthy Infants of G1 and G2 Human-Bovine Rotavirus Reassortant Vaccine in a New Buffer/Stabilizer Liquid Formulation (Protocol 003).	1769
2.1.4	MRL Clinical Study Report (Synopsis), Multicenter Study: Safety and Tolerability of Oral, Live G4 Human- Bovine Reassortant Rotavirus Vaccine in Healthy Adults and Healthy Infants (Protocol 004).	1775
2.1.5	MRL Clinical Study Report (Synopsis): Safety, Immunogenicity, and Efficacy in Healthy Infants of G1, G2, G3, G4, and P1 Human-Bovine Rotavirus Reassortant Vaccine (Protocol 005).	1779
2.1.6	MRL Clinical Study Report (Synopsis), Multicenter Study: Study of the Efficacy, Safety, and Immunogenicity of RotaTeq TM at Expiry Potency (Protocol 007).	1787
2.1.7	MRL Clinical Study Report (Synopsis), Multicenter Study: Comparison of the Immunogenicity and Safety of Three Consistency Lots of RotaTeq [™] in Healthy Infants (Protocol 009).	1793
CATEGORY 3:	STUDY DOCUMENTS	
3.1	Principal Authors' and Investigator's Signatures	1798
3.2	Audit Information Sheet	1800
3.3	Protocol and Protocol Amendment(s)	
3.3.1	Protocol 006-00	1802
3.3.2	Protocol Amendment 006-01	1900
3.3.3	Protocol Amendment 006-02	2057
3.3.4	Protocol Amendment 006-03	2209
3.3.5	Protocol Amendment 006-04	2390
3.4	Protocol-Specific Informed Consent	
3.4.1	Safety Cohort Consent Form	2555
3.4.2	Detailed Safety Cohort Consent Form	2561
3.4.3	Taiwan Cohort Consent Form	2567

CLINICAL STUDY REPORT I. SYNOPSIS

V260

Live Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine for Oral Administration

Quadrivalent Vaccine Containing Serotypes G1, G2, G3, and P1

PROTOCOL TITLE/NO.: Sat	ety, Tolerability, and Imm	unogenicity of Live	#001
Quadrivalent Human-Bovine Rotav	rirus Reassortant Vaccine in He	ealthy Adults	
INVESTIGATOR(S)/STUDY CEN	TER(S): Paul A. Offit, M.D	., Philadelphia, PA, U.S.A.	
PRIMARY THERAPY PERIOD:	19-Jun-1993 to 08-Jul-1993;	CLINICAL PHASE:	I
Clinical Data Cutoff Date: 04-	Dec-1996; Serology Cutoff		
Date: 11-Nov-1996; Study Comple	etion Date: 08-Jul-1993.		
DURATION OF TREATMENT:	Single dose/14-day follow-up.		
OBJECTIVE(S): Primary Object	ive: To determine if the vacc	tine is safe in healthy immune	adults.
Secondary Objective: To investig	gate immune responses after a	a single dose of quadrivalent	vaccine
when administered orally to healthy	adults.		
STUDY DESIGN: Double-blind, 1	andomized, placebo-controlled	l trial.	
SUBJECT ACCOUNTING:			
	Rotavirus Vaccine	Placebo	
ENTERED: Total	20	11	
Male (age range-years)	10 (22 to 40)	5 (21 to 42)	
Female (age range-years)	10 (19 to 47)	6 (22 to 34)	
COMPLETED:	19	11	
DISCONTINUED: Total	1	0	
Clinical adverse experience	0	0	
Laboratory adverse experiences	0	0	
Refused further participation	1	0	
DOSAGE/FORMULATION NOS.:	Regimen: A 1.0-mL dose o	f vaccine/placebo orally admir	istered,
following an 8-hour overnight f	ast. One-half hour before	administration, subjects were	; given
4 teaspoons of MAALOX [™] (mag	nesia alumina oral suspension	n antacid, Novartis Consumer	Health,
Inc.) to ensure uniform gastric b	ouffering and were asked to	refrain from eating for 1 hor	ur after
Inc.) to ensure uniform gastric b	ouffering and were asked to	refrain from eating for 1 ho	ur after

administration of vaccine/placebo. <u>Clinical Material</u>: Quadrivalent human-bovine rotavirus reassortant vaccine, Lot 1340A/C-Y560A, 1.2-mL vial. This vaccine contained serotypes G1, G2, G3, and P1 each with an estimated final titer of 1 x 10⁷ plaque-forming units (PFU)/mL in (b) (4) Medium (b) (4) (b) (4) with (b) (4) at (b) (4) at (b) (4) at (b) (4) and (b) (4) at (b) (4) . Placebo, Lot 1341/C-Y561, 1.2-mL vial. This placebo contained (b) (4) Medium (b) (4) with (b) (4) at (b) (4) at (b) (4) at (b) (4)

- DIAGNOSIS/INCLUSION CRITERIA: Healthy adults 18 years of age or older who had no: known hypersensitivity to any component of the rotavirus vaccine, e.g., (b) (4); known or suspected impairment of immunologic function; fever, ≥100°F (oral) at the time of immunization; clinical evidence of chronic or active gastrointestinal illness prior to immunization; other vaccines given within 14 days prior to administration of study vaccine; history of drug or alcohol abuse. Subjects were not pregnant or expecting to conceive during the study period. Subjects must have agreed to use an acceptable method of birth control for 2 weeks after the immunization. Abstinence was considered an acceptable method of birth control. Subjects did not have any condition which, in the opinion of the investigator, might have interfered with the evaluation of the study objectives.
- **EVALUATION CRITERIA:** Immunogenicity Evaluation: Serum neutralizing antibody levels (for each of G1, G2, G3, P1, bovine WC3 strain, and human W179 strain specificities). Safety Evaluation: Incidence of serious vaccine-related adverse experiences (Days 0 to 14 postvaccination); fecal vaccine virus shedding (Days 2 to 7 postvaccination); temperature elevations (Days 0 to 14 postvaccination); and serum alanine transaminase (ALT) levels (Days 0 and 14 postvaccination).

BC1421.DOC VERSION 21.1 APPROVED

Restricted Confidential - Limited Access

09-Feb-2004

V260

Live Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine. Oral Rotavirus Gastroenteritis

Protocol 002

CSR SYNOPSIS (CONT.)

-2-

DOSAGE/FORMULATION NOS.:

Regimen: Three (3) doses of the clinical material were administered to each subject orally. The volume of each dose was 1.0 mL of quadrivalent G1, G2, G3, and P1 human-bovine reassortant rotavirus vaccine or placebo. Dose 1 was given on Day 0, Dose 2 was given 6 to 8 weeks after Dose 1, and Dose 3 was given 6 to 8 weeks after Dose 2.

CLINICAL MATERIAL:

¥7		D	Potency	
Vaccine	Lot Number-Fill Number	Dosage	(PFU/dose)	Раскаде
Live rotavirus vaccine	1340A/C-Y560A	1.0 mL	4 x 10 ⁷	Code-labeled vial kept at (b) (4)
Placebo	1341/C-Y561	1.0 mL	0	Code-labeled vial kept at (b) (4)

DIAGNOSIS/INCLUSION CRITERIA: Healthy infants, 2 to 6 months of age who had no known or suspected impairment of immunologic function; no prior administration of any rotavirus vaccine; no fever (defined as a rectal temperature of ≥100.4°F) at the time of immunization; no history of chronic diarrhea or failure to thrive; no clinical evidence of active gastrointestinal disease; no other vaccines given within (+/-) 14 days of any dose of vaccine; no condition that, in the opinion of the investigator, could have interfered with the evaluation of the study objectives; and no infant who resided in a household with an immunocompromised individual.

EVALUATION CRITERIA: Efficacy: The case definition for rotavirus gastroenteritis was that a subject must have met both of the following criteria: $(1) \ge 3$ watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting. (2) Rotavirus must have been identified in a stool specimen taken within 14 days of the onset of symptoms. Immunogenicity: Serum samples, taken Predose 1 and Postdose 3, were tested by enzyme immunoassay (EIA) for serum neutralizing antibody (SNA) against G1, G2, G3, P1a, P1G1, G6, and P7. Serum was also tested for anti-rotavirus IgA and IgG. Stool samples, taken Predose 1 and Postdose 3, were tested to record any adverse experiences that occurred within 14 days after any vaccination. Temperatures were recorded daily for 7 days after each administration of vaccine/placebo. Stool samples for viral shedding were obtained from all participants between Day 3 and Day 5 after Dose 1. In addition, the Philadelphia study site collected stool samples for vaccine viral shedding 1 to 2, 3 to 5, 7 to 9, and ~15 days following each dose.

STATISTICAL PLANNING AND ANALYSIS:

Efficacy: The primary efficacy hypothesis that the quadrivalent rotavirus vaccine provides efficacy against rotavirus disease throughout one rotavirus season was tested using an exact conditional procedure. The primary hypothesis in the protocol refers to 80% efficacy, which is the expected efficacy that was used for power and sample size calculations; however, the primary hypothesis was tested for vaccine efficacy >0.0% relative to placebo, as noted in the Data Analysis Plan (DAP). A point estimate and exact two-sided 95% confidence interval for vaccine efficacy were also calculated. In order for the quadrivalent rotavirus vaccine to be declared efficacious (i.e., in order to reject the null hypothesis), the lower bound on the confidence interval for vaccine efficacy had to exceed 0%. If there were 160 evaluable infants per group, and assuming that the true incidence of disease in the placebo group would be 10% and that the vaccine would be 80% efficacious in the prevention of rotavirus disease, there would be 80% power to reject the primary null hypothesis. One hundred eighty (180) evaluable infants per group.

CSR Synopsis_V260_002_P002 VERSION 2.1 APPROVED Restricted © Confidential – Limited Access

09-Dec-2003

V260 G1 G2 Reassortant Rotavirus Vaccine Live (Human-Bovine) Oral Rotavirus Gastroenteritis

CSR SYNOPSIS (CONT.) Protocol 003

-2-

SUBJECT ACCOUNTING:

	Rotavirus (G1, G2) Vaccine				Placebo
	1.0 mL – No Buffer (Group 1)	1.0 mL – 1x Buffer (Group 3)	2.5 mL – 1x Buffer (Group 5)	1.0 mL – Conc. Buffer (Group 7)	(Groups 2, 4, 6, and 8 Combined)
ENTERED: Total	142	150	147	142	150
Male (age range-weeks)	64 (8 to 21)	74 (8 to 21)	76 (6 to 21)	77 (8 to 21)	79 (8 to 21)
Female (age range-weeks)	78 (6 to 21)	76 (8 to 21)	71 (7 to 21)	65 (8 to 21)	71 (8 to 21)
COMPLETED:	136	138	137	132	138
DISCONTINUED: Total	6	12	10	10 .	12
Clinical adverse experience	0	1	0	2	2
Refused further participation	3	6	6	5	6
Lost to follow-up	3	5	4	3	4

DOSAGE/FORMULATION NOS.: Regimen: Three (3) doses of the clinical material were administered to each subject orally. The volume of administration was either 1.0 mL or 2.5 mL, depending upon the subject's group assignment. Each dose was provided under the following schedule: Dose 1, given on Day 0.

Dose 2, given between Days 42 and 56.

Dose 3, given between Days 84 and 98.

Group	Prefeeding	Vaccine Vol (mL)	Buffer/Stabilizer	PFU/Dose
1	Yes	1.0	None	1x 10 ⁷ PFU
2†	Yes	1.0	None	0
3	No	1.0	1x	1x 10 ⁷ PFU
4†	No	1.0	1x	0
5	No	2.5	1x	1x 10 ⁷ PFU
6†	No	2.5	1x	0
7	No	1.0	Concentrate	1x 10 ⁷ PFU
8†	No	1.0	Concentrate	0
[†] Placebo.				

CLINICAL MATERIAL: G1 and G2 human-bovine reassortant rotavirus vaccine, a live virus vaccine, Lots No. 1507/W-D152, 1493/W-C971, 1494/W-C972, and 1495/W-C973. The vaccine contained serotypes G1 and G2, each with an estimated final titer of 5 x 10⁶ PFU/reassortant or a total of 1x10⁷ PFU G1 and G2 human-bovine rotavirus reassortant vaccine per dose, in (b) (4) (b) (4). Placebo represented buffer alone; i.e., without rotavirus vaccine, Lots No. 1506/W-D151, 1489/W-C967, 1490/W-C968, and 1491/W-C969.

CLINICAL STUDY REPORT I. SYNOPSIS

V260

G4 Human-Bovine Reassortant Rotavirus Vaccine, Oral Rotavirus gastroenteritis

PROTOCOL TITLE/NO.: Safety and Tolerability of Oral, Live	G4 Human-Bovine	#004
Reassortant Rotavirus Vaccine in Healthy Adults and Healthy Infants	÷	
INVESTIGATOR(S)/STUDY CENTER(S): Multicenter (02) U.S.		
PRIMARY THERAPY PERIOD: 19-Mar-1998 to 07-Jul-1998	CLINICAL PHASE:	IIb
(last dose of therapy).		
Study completed: 18-Aug-1998.		
Clinical Case Report Form and Laboratory Data In-House Cut-off		
Date: 10-Sep-1999.		
DURATION OF TREATMENT: Single dose/42-day follow-up.		
OBJECTIVE(S): To assess that the G4-reassortant rotavirus vaccine i	s generally safe and well to	plerated.

in order to include it in a multivalent oral live rotavirus vaccine.

STUDY DESIGN: Double-blinded, placebo-controlled randomized study organized in 2 stages. Stage 1 was conducted in healthy adults; Stage 2 was conducted in healthy infants, after subjects from Stage 1 had been followed 14 days without any vaccine-related serious adverse experiences. Within each stage, subjects were randomized between vaccine and placebo groups at a ratio of 2:1.

SUBJECT ACCOUNTING:

	Adults			Infants		
	(A	ge Range in Yea	rs)	· (A	ge Range in Week	(3)
				Rotavirus		
	Rotavirus			(G4 Vaccine)		
	(G4 Vaccine)	Placebo	Total	Vaccine	Placebo	Total
ENTERED: Total	10	5	15	47	23	70
Male (age range)	6 (26 to 53)	3 (23 to 30)	9 (23 to 53)	25 (8 to 21)	13 (9 to 21)	38 (8 to 21)
Female (age range)	4 (27 to 54)	2 (28 to 32)	6 (27 to 54)	22 (9 to 21)	10 (8 to 21)	32 (8 to 21)
COMPLETED:	10	5	15	46	22	68
DISCONTINUED: Total	0	0	0	1	1	2
Clinical adverse experience	0	0	0	0	0	0
Deviation from protocol	0	0	0	0	0	0
Refused further participation	0	0	0	0	0	0
Lost to follow-up	0	0	0	1	1	2

DOSAGE/FORMULATION NOS.:

Regimen: A single, 1-mL dose of clinical material, vaccine or placebo, was administered orally to each subject on Day 0. The vaccine was given approximately one-half hour after the administration of a buffering agent.

Clinical Trial Material: The	vaccine contained	G4 human-	bovine reass	sortant rotaviru	s with an esti	mated
final titer of 10^7 plaque-fo	rming units (PFU	J) in a 1-m	L dose. T	he vaccine co	mposition ind	cluded
(b) (4) Medium	(b) (4)	at	(b) (4)	at	(b) (4)	at
(b) (4) and sucrose	(b) (4)	, Lot No.	. V260-OSO-	001-D001.	Trace
components of fetal bovine	serum may also	have been	present in	the vaccine.	The placeb	o was
composed of (b) (4) Med	ium (b)	(4)	at	(b) (4)	at (b) (4)	, and
Sucrose (b) (4)	, Lot No	o. 1506/W-D	151.			-

CSR SYNOPSIS (CONT.) Protocol 005

V260

Live Pentavalent Human-Bovine Rotavirus Reassortant Vaccine Oral; Rotavirus Gastroenteritis

-2-

SUBJECT ACCOUNTING:

14.				Group 4 Rotavirus (G1, G2, G3,	Group 5 Rotavirus	
	Rotavirus (G1 Group 1 5x10 ⁶ PFU/	, G2, G3, G4, an Group 2 1 6x10 ⁶ PFU/	Group 3 5x10 ⁵ PFU/	G4) Vaccine 5x10 ⁶ PFU/	(P1) Vaccine 5x10 ⁶ PFU/	Group 6
	Reassortant	Reassortant	Reassortant	Reassortant	Reassortant	Placebo
Entered:	375	328	324	270	327	322
Male (age range - months)	201 (2 to 8)	179 (2 to 8)	156 (2 to 8)	134 (2 to 8)	165 (2 to 8)	152 (2 to 8)
Female (age range – months)	174 (2 to 8)	149 (2 to 8)	168 (1 to 9)	136 (2 to 8)	162 (2 to 8)	170 (2 to 8)
Vaccinated At:						
Vaccination Visit 1:	375	328	324	270	327	322
Vaccination Visit 2:	358	305	315	256	317	307
Vaccination Visit 3:	349	299	307	251	310	297
Completed First Season:	348	295	306	248	307	296
Discontinued:	27	33	18	22	20	26
Clinical adverse experience	0	0	0	0	0	0
Deviation from protocol	0	0	0	0	0	0
Refused further	12	13	12	7	6	3
participation						
Lost to follow-up	1	4	1	3	2	1
Clinical adverse experience	14	16	5	12	12	22
 discontinued test vaccine 					and a second	

DOSAGE/FORMULATION NOS.:

Regimen: Three (3) doses of the clinical material were administered to each subject orally. The volume of each dose was 1.0 mL of vaccine (high-dose, middle-dose, or low-dose pentavalent; quadrivalent; or monovalent) or placebo. Dose 1 was administered on Day 0, Dose 2 was administered 4 to 8 weeks after Dose 1, and Dose 3 was administered 4 to 8 weeks after Dose 2.

Clinical Material:

- **Group 1:** G1, G2, G3, G4, and P1 serotype of human-bovine rotavirus reassortants, with an estimated final titer of $5x10^6$ plaque-forming units (PFU)/reassortant, Lot No. V260 OSO 003 E001.
- **Group 2:** G1, G2, G3, G4, and P1 serotype of human-bovine rotavirus reassortants, with an estimated final titer of 1.6x10⁶ PFU/reassortant, Lot No. V260 OSO 003 C001.

Group 3: G1, G2, G3, G4, and P1 serotype of human-bovine rotavirus reassortants, with an estimated final titer of 5×10^5 PFU/reassortant, Lot No. V260 OSO 003 B001.

Group 4: G1, G2, G3, and G4 serotype of human-bovine rotavirus reassortants, with an estimated final titer of 5x10⁶ PFU/reassortant, Lot No. V260 OSO 002 C001.

Group 5: P1 serotype of human-bovine rotavirus reassortants, with an estimated final titer of 5×10^6 PFU/reassortant, Lot No. V260 OSO 004 E001

Group 6: Contained no human-bovine rotavirus reassortants, Lot No. PV260 OSO 02 A001.

All Groups	(including p	lacebo) contained	(b) (4) Medium	(b) (4)	with	(b) (4)	at
	(b) (4)	at	(b) (4)	and	sucrose	(b) (4)	
(h) (A)	The week	ing manna (Cran	a 1 to 5) contained (h	A (A) at		(b) (4)	

CSR Synopsis_V260_005_P005 VERSION 9.6 APPROVED Restricted & Confidential – Limited Access

09-Apr-2004

CSR SYNOPSIS (CONT.) Protocol 007

V260 Rotavirus Vaccine, Live, Oral, Pentavalent -2-

DOSAGE/FORMULATION NOS.:

- **Regimen:** Three (3) doses of the clinical material were administered to each subject orally. The volume of each vaccination was 2.0 mL of vaccine or placebo. Vaccination 1 was to be administered on Day 1, Vaccination 2 was to be administered 28 to 70 days after Vaccination 1, and Vaccination 3 was to be administered 28 to 70 days after Vaccination 2.
- **Clinical Material:** RotaTeqTM at expiry potency (Lot Nos. V260 VAO 019Q001 and V260 VAO 019Q002) contained approximately (b) (4 mg of sucrose, approximately (b) mg of sodium citrate. approximately (b) mg of sodium phosphate, (b) mL of tissue culture medium, and no greater than (b) (4) mg of polysorbate-80, and human-bovine rotavirus reassortants G1, G2, G3, G4, and P1 with an estimated final aggregate potency of ~1.1 x10⁷ infectious units (IU)/dose in approximately 2.0 mL of buffer/stabilizer. Theoretical calculation of (b) (4) material (b) (4) was (b) $\mu g/dose.$ Trace components of fetal bovine serum may have also been present.

The placebo (Lot No. PV260 VAO 009A009) was approximately 2.0 mL per dose that contained approximately ^(b) (4)mg of sucrose, approximately ^(b) (4)mg of sodium citrate, approximately ^(b) (4)mg of sodium phosphate, and no greater than ^(b) (4)mg of polysorbate-80. **DIAGNOSIS/INCLUSION CRITERIA** Healthy infants, 6 through 12 weeks of age, who had no

DIAGNOSIS/INCLUSION CRITERIA^{™™} Healthy infants, 6 through 12 weeks of age, who had no known history of congenital abdominal disorders, intussusception, or abdominal surgery; no known or suspected impairment of immunological function; no known hypersensitivity to any component of the rotavirus vaccine; no prior receipt of any rotavirus vaccine; no fever, with a rectal temperature ≥38.1°C (≥100.5°F) at the time of immunization; no history of known prior rotavirus disease, chronic diarrhea, or failure to thrive; no clinical evidence of active gastrointestinal illness. (Note that infants with gastroesophageal reflux disease [GERD] were permitted to participate in the study as long as the GERD was well controlled with or without medication.); no receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 2 weeks prior to vaccination; did not reside in a household with an immunocompromised person; no prior receipt of a blood transfusion or blood products, including immunoglobulins; no receipt of oral poliovirus vaccine (OPV) during the course of the study or within 42 days prior to the first dose of vaccine/placebo; any infant who could not be adequately followed for safety by telephone or home visit; and no condition, which, in the opinion of the investigator, may have interfered with the evaluation of the study objectives.

EVALUATION CRITERIA:

- Efficacy: The case definition for rotavirus gastroenteritis required subjects to meet both of the following criteria: (1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and (2) Rotavirus detected by enzyme immunoassay (EIA) in a stool specimen taken within 14 days after the onset of symptoms. All rotavirus-positive stools were evaluated for serotype identification by polymerase chain reaction (PCR). Only naturally-occurring rotavirus AGEs caused by the human rotavirus G- serotypes in the vaccine were included in the primary analysis.
- **Immunogenicity:** In a subset of approximately 175 subjects, antibody responses to the vaccine were evaluated by several assays. Serum samples were collected before Dose 1 and approximately 42 days after Dose 3. Serum was tested by modified enzyme-linked immunosorbent assay (ELISA) for serum neutralizing antibodies (SNA) against the rotavirus serotypes contained within the vaccine (G1, G2, G3, G4, P1, and WC3 (the WC3 serotype is also characterized as G6 and P7[5] throughout this document)). Serum anti-rotavirus IgA was also evaluated.
- Safety: The subjects' parent/legal guardians were asked to record any adverse experiences that occurred within 42 days following any vaccination. The subjects' parent/legal guardians were instructed to record daily for the first 7 days following vaccination the subject's temperature, behavioral changes, and the number of episodes of vomiting and/or diarrhea.

CSR Synopsis_V260_007_P007 VERSION 3.0 APPROVED Restricted & Confidential – Limited Access 21-Dec-2004

CSR SYNOPSIS (CONT.) Protocol 009

V260 Rotavirus Vaccine, Live, Oral, Pentavalent

-2-

DOSAGE/FORMULATION NOS.:

Regimen: Three (3) doses of the clinical material were to be administered to each subject orally. The volume of each vaccination was approximately 2.0 mL of vaccine or placebo. Vaccination 1 was administered on Day 1, Vaccination 2 was to be administered 28 to 70 days after Vaccination 1, and Vaccination 3 was to be administered 28 to 70 days after Vaccination 2.

Clinical Material: RotaTeqTM (Lot 1 No.: V260 VAO 020 R001; Lot 2 No.: V260 VAO 020 R002; and Lot 3 No.: V260 VAO 020 R003) was approximately 2.0 mL per dose that contained approximately (b) (4) mg of sucrose, approximately (b) (4) mg of sodium citrate, approximately (b) mL of tissue culture medium, and no greater than (b) mL of polysorbate 80, and human-bovine rotavirus reassortants G1, G2, G3, G4, and P1 in approximately 2.0 mL of buffer/stabilizer with a measured aggregate potency of 8.81 X 10⁷ Infectious Units (IU)/dose, 8.01 X 10⁷ IU/dose, and 6.91 X 10⁷ IU/dose for Lot 1, Lot 2, and Lot 3, respectively.

The placebo (Lot No. PV260 VAO 022 P001) was approximately 2.0 mL per dose that contained approximately ^(b) mg of sucrose, approximately ^(b) ng of sodium citrate, approximately ^(b) (a) mg of sodium phosphate, ^(b) mL of tissue culture medium, and no greater than ^(b) mg of polysorbate 80.

DIAGNOSIS/INCLUSION CRITERIA: Healthy infants, 6 through 12 weeks of age, who had no known history of congenital abdominal disorders, intussusception, or abdominal surgery; no known or suspected impairment of immunological function; no known hypersensitivity to any component of the rotavirus vaccine; no prior receipt of any rotavirus vaccine; no fever, with a rectal temperature ≥38.1°C (≥100.5°F) at the time of immunization; no history of known prior rotavirus disease, chronic diarrhea, or failure to thrive; no clinical evidence of active gastrointestinal illness. (Note that infants with gastroesophageal reflux disease [GERD] were permitted to participate in the study as long as the GERD was well controlled with or without medication.); no receipt of a blood transfusion or blood products, including immunoglobulins; no receipt of oral poliovirus vaccine (OPV) during the course of the study or within 42 days prior to the first dose of vaccine/placebo; any infant who could not be adequately followed for safety by telephone or home visit; and no condition, which, in the opinion of the investigator, may have interfered with the evaluation of the study objectives.

EVALUATION CRITERIA:

Immunogenicity: Antibody responses (SNA Postdose 3 GMTs against rotavirus serotypes G1, G2, G3, G4, and P1 and serum anti-rotavirus IgA) to RotaTeqTM/placebo were evaluated in all subjects. These assays were performed on one serum sample collected from each subject approximately 42 days Postdose 3. In addition, Predose 1 serum samples were to be collected in a subset of approximately 140 subjects (approximately 40 subjects per vaccine lot and approximately 20 subjects in the placebo group) at predetermined study sites. Predose 1 serum samples were assayed for SNA against rotavirus serotypes G1, G2, G3, G4, and P1.

Safety: The subjects' parent/legal guardians were asked to record any adverse experiences that occurred within 42 days following any vaccination. The subjects' parent/legal guardians were instructed to record daily for the first 7 days following vaccination the subject's temperature, behavioral changes, and the number of episodes of vomiting and diarrhea.

E. STUDY DESIGN (CONT.)

Each container will be labeled with double-panel tear-off labels containing the following: unique vial identification number, packing identification number, rotavirus vaccine or placebo, protocol (006) V260, fill volume, dosing instructions (follow protocol for dosing instructions/for oral route only), and storage conditions. The tear-off portion of the label will also contain the unique vial identification number and a space for transcribing the dose number and the allocation number assigned to the patient by the IVRS. This tear-off label will be affixed to the L-page in the subject workbooklet.

All clinical material (i.e., vaccine and placebo) must be accounted for by appropriately documenting the administration (or wasting) of each vial. Empty or partially empty vials and vials that have been thawed but not used must be disposed of accordingly to standard methods for handling medical infectious hazardous waste.

A sample label will be similar to the following:

MERCK RESEARCH LABORATORIES # XXXXXX WP-XXXX SUBJECT NO. DOSE NO. ROTAVIRUS VACCINE/PLACEBO ORAL SOLUTION 2.0ML DOSE ADMINISTER PER PROTOCOL 006 (V260) S###### STORE REFRIGERATED(2-8°C) KLIINISEEN TUTKIMUKSEEN/FOR KLINISK PROVNING Caution: New Drug Limited by Federal (U.S.A.) Law to Investigational Use

1) Description of the Vaccine to be Administered

Vaccine administered to Group 1 contains human-bovine rotavirus reassortants G1, G2, G3, G4, and P1 with an estimated final titer of (b) (4) (b) (4) in a 2.0-mL dose. A vaccine dose contains approximately $(a)_{(4)}$ g sucrose, (b) (4) citrate, (b) (4) phosphate, (b) (4) mL tissue culture medium, and no greater than (b) (4) mg polysorbate 80. (b) (4) (b) (4) is present in a vaccine dose. Trace components of fetal bovine serum may also be present.

2) <u>Description of the Placebo</u>

Placebo administered to Group 2 is a 2.0-mL dose that contains approximately $\binom{(b)}{(4)}$ g sucrose, $\binom{(b)}{(4)}$ citrate, $\binom{(b)}{(4)}$ phosphate, $\binom{(b)}{(4)}$ mL tissue culture medium, and no greater than $\binom{(b)}{(4)}$ mg polysorbate 80.

/V260/CP/BP2895.DOC APPROVED Worldwide Protocol 23-Jun-2000

E. <u>STUDY DESIGN</u> (CONT.)

A sample label will be similar to the following:

MERCK RESEARCH LABORATORIES # XXXXXX WP-XXXX SUBJECT NO. DOSE NO. ROTAVIRUS VACCINE/PLACEBO ORAL SOLUTION 2.0ML DOSE ADMINISTER PER PROTOCOL 006 (V260) S##### STORE REFRIGERATED(2-8°C) KLIINISEEN TUTKIMUKSEEN/FOR KLINISK PROVNING Caution: New Drug Limited by Federal (U.S.A.) Law to Investigational Use

Additional country-specific label requirements will be used on the vaccine/placebo vial box for clinical use as required in other individual countries.

Concomitant use vaccine vials will receive a single panel, open label including at least the following information: product, lot number, expiration date, packaging control number, applicable storage conditions, and dosing information. PREVNARTM is in short supply at the time of writing this protocol. If it is not available for Merck & Co., Inc. to supply, the subset of subjects in the U.S. concomitant use portion of the study may still receive PREVNARTM provided by their local physician. The lot number of the vial will be documented on the appropriate worksheet. Note: If PREVNARTM is provided locally by the physician, the single panel, open label will not be used on PREVNARTM.

e. Description of Clinical Material to be Administered

Description of RotaTeqTM, the Study Vaccine to be Administered

RotaTeqTM, which will be administered to Group 1, contains human-bovine rotavirus reassortants G1, G2, G3, G4, and P1 with an estimated final dose of (b)(4) in a 2.0-mL dose. A vaccine dose contains (b) g sucrose, (b)(4) citrate. (b)(4) phosphate, (b) (a) mL tissue culture medium, and no greater than (b) mg polysorbate 80. (b)(4) is present in a vaccine dose. Trace components of fetal bovine serum may also be present.

Description of the Placebo: Placebo, which will be administered to Group 2, is a 2.0-mL dose that contains $\begin{bmatrix} b \\ 4 \\ 4 \end{bmatrix}$ g sucrose, $\begin{bmatrix} (b) & (4) \\ (4) \end{bmatrix}$ citrate, $\begin{bmatrix} (b) & (4) \\ (4) \end{bmatrix}$ mL tissue culture medium, and no greater than $\begin{bmatrix} (b) & (4) \\ (4) \end{bmatrix}$ mg polysorbate 80.

24-Jan-2002

E. <u>STUDY DESIGN</u> (CONT.)

A sample label will be similar to the following:

MERCK RESEARCH LABORATORIES # XXXXXX WP-XXXX SUBJECT NO. DOSE NO. ROTAVIRUS VACCINE/PLACEBO ORAL SOLUTION 2.0ML DOSE ADMINISTER PER PROTOCOL 006 (V260) S##### STORE REFRIGERATED(2-8°C) KLIINISEEN TUTKIMUKSEEN/FOR KLINISK PROVNING Caution: New Drug Limited by Federal (U.S.A.) Law to Investigational Use

Additional country-specific label requirements will be used on the vaccine/placebo vial box for clinical use as required in other individual countries.

Concomitant use vaccine vials will receive a single panel, open label including at least the following information: product, lot number, expiration date, packaging control number, applicable storage conditions, and dosing information. PREVNAR[™] is in short supply at the time of writing this protocol. If it is not available for Merck & Co., Inc. to supply, the subset of subjects in the U.S. concomitant use portion of the study may still receive PREVNAR[™] provided by their local physician. The lot number of the vial will be documented on the appropriate worksheet. Note: If PREVNAR[™] is provided locally by the physician, the single panel, open label will not be used on PREVNAR[™].

e. Description of Clinical Material to be Administered

Description of RotaTeqTM, the Study Vaccine to be Administered

Description of the Placebo: Placebo, which will be administered to Group 2, is a 2.0-mL dose that contains $\begin{bmatrix} 1 \\ 2 \end{bmatrix}$ g sucrose, $\begin{bmatrix} (b) & (4) \end{bmatrix}$ citrate, $\begin{bmatrix} (b) & (4) \end{bmatrix}$ phosphate, $\begin{bmatrix} b & (4) \end{bmatrix}$ mL tissue culture medium, and no greater than $\begin{bmatrix} (b) & (4) \end{bmatrix}$ (4) mg polysorbate 80.

18-Apr-2002

E. <u>STUDY DESIGN</u> (CONT.)

Additional country-specific label requirements will be used on the vaccine/placebo dose package box for clinical use as required in other individual countries.

g. Description of Clinical Material to be Administered

Description of RotaTeqTM, the Study Vaccine to be Administered

RotaTeq[™], which will be administered to Group 1, contains human-bovine rotavirus reassortants G1, G2, G3, G4, and P1 with an estimated final dose of (b) (4) in a 2.0-mL dose. A vaccine dose contains (b) g sucrose, (c) (4) citrate, (b) (4) phosphate, (c) mL tissue culture medium, and no >^{(b) (4)} mg polysorbate 80. (b) (4) is present in a vaccine dose. Trace components of fetal bovine serum may also be present.

Description of the Placebo: Placebo, which will be administered to Group 2, is a 2.0-mL dose that contains $\binom{(b)}{(4)}$ g sucrose, $\binom{(b)}{(4)}$ citrate, $\binom{(b)}{(4)}$ phosphate, $\binom{(b)}{(4)}$ tissue culture medium, and no > $\binom{(b)}{(4)}$ mg polysorbate 80.

Other Childhood Vaccines to be Administered Concomitantly With RotaTeqTM in the Subset of Subjects in the U.S. Efficacy Portion of the Study

U.S. Concomitant Efficacy Sites:

COMVAXTM: (Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B[Recombinant] Vaccine): Each 0.5-mL dose contains 7.5 mcg of purified capsular polysaccharide (PRP) of Haemophilus b (b) (4) 125 mcg of outer membrane protein complex (Hib) (OMPC) of the B11 strain of *Neisseria meningitidis* serogroup B and 5.0 mcg of hepatitis B surface antigen (HBsAg). Each dose contains 225 mcg aluminum as (b) (4) , and 35 mcg of sodium borate (decahydrate) as a pH stabilizer, in 0.9% sodium chloride. The vaccine contains (b) (4) . The vaccine is supplied in 0.5-mL single dose vials.

Included in each shipment of $COMVAX^{TM}$ will be a (b) (4)

Prior to receiving a shipment, site personnel should review the *Instructions to Site* and contact the Medical Program Coordinator (MPC) with any questions.

56

A sample label will be similar to the following:

MERCK RESEARCH LABORATORIES# XXXXXX WP-XXXX SUBJECT NO. DOSE NO.ROTAVIRUS VACCINE/PLACEBO ORAL SOLUTION2 ML DOSE ADMINISTER PER PROTOCOL 006 (V260)S#####STORE REFRIGERATED(2-8°C)KLIINISEEN TUTKIMUKSEEN/FOR KLINISK PROVNINGCaution: New Drug Limited by Federal (U.S.A.) Law to Investigational Use

Additional country-specific label requirements may be used on the vaccine/placebo vial or dose package box for clinical use as required in other individual countries.

U.S. Concomitant Use

Concomitant use vaccine vials will be labeled with a single panel, open label including at least the following information: product, lot number, expiration date, packaging control number, applicable storage conditions, and dosing information. PREVNARTM has been in short supply over the course of the study. If it is not available for Merck & Co., Inc. to supply, the subset of subjects in the U.S. concomitant use portion of the study may still receive PREVNARTM provided by their local physician. The lot number and expiration date of the vial will be documented on the appropriate worksheet. Note: If PREVNARTM is provided locally by the physician, the single panel, open label will not be used on PREVNARTM.

f. Description of Clinical Material to be Administered

Description of RotaTeqTM, the Study Vaccine to be Administered

RotaTeqTM, which will be administered to Group 1, contains human-bovine rotavirus reassortants G1, G2, G3, G4, and P1 with an estimated final dose **range of 6.5 x 10⁷ IU to 1.2 x 10⁸ IU** in an approximate 2-mL dose. RotaTeqTM is a buffered, liquid product that is stored at 4°C, and will be marketed in a plastic container designed for direct oral delivery. A vaccine dose contains $\binom{(b)}{(4)}$ g sucrose, $\binom{(b)}{(4)}$ citrate, $\binom{(b)}{(4)}$ mp polysorbate 80. (b) (4) is present in a vaccine dose. Trace components of

(b) (4) is present in a vaccine dose. Trace components of fetal bovine serum may also be present.

Description of the Placebo: Placebo, which will be administered to Group 2, is approximately a 2-mL dose that contains $\binom{(b)}{14}$ g sucrose, $\binom{(b)}{4}$ citrate, $\binom{(b)}{4}$ phosphate, $\binom{(b)}{4}$ -mL tissue culture medium, and no greater than polysorbate 80.

13-Feb-2004

Reference P007

Study of the Efficacy, Safety, and Immunogenicity of RotaTeq[™] at Expiry Potency

CLINICAL STUDY REPORT

Study of the Efficacy, Safety, and Immunogenicity of RotaTeq[™] at Expiry Potency

TABLE OF CONTENTS

				Application Starting Page
I.	SYI	NOPS	JIS	20
II.	CO	MPRI	EHENSIVE STUDY SUMMARY	26
	1.	Intr	oduction	26
	2.	Ethi	ics	31
		2.1	Ethics Review Committee/Independent Ethics Committee/Institutional Review Board	31
		2.2	Ethical Conduct of the Study	31
		2.3	Subject Information and Informed Consent Form	31
	3.	Inve	estigators and Study Administrative Structure	33
		3.1	Investigators	33
		3.2	Independent Committees for the Assessment of Safety	33
		3.3	Laboratories	33
		3.4	Contract Research Organizations	35
		3.5	Authors of Clinical Study Report (CSR)	35
	4.	Stuc	ly Hypotheses and Objectives	36
		4.1	Hypotheses	36
		Z	4.1.1 Primary	36
		L	4.1.2 Secondary	36
		4.2	Objectives	36
		Z	4.2.1 Primary	36
		4	1.2.2 Secondary	36
	5.	Inve	estigational Plan	37
		5.1	Overall Study Design and Plan: Description	37
		5.2	Discussion of Study Design, Including the Choice of Control Groups	42

TABLE OF CONTENTS (CONT.)

			Application Starting Page
5.3 Sel	ection o	f Study Population	42
5.3.1	Inclus	ion Criteria	43
5.3.2	Exclu	sion Criteria	43
5.3.3	Disco: Study	ntinuation of Subjects From Therapy or Observation	44
5.4 Tre	atments		44
5.4.1	Treatr	nents Administered	44
5.	4.1.1 I	RotaTeq [™] at Expiry Potency Versus Placebo	44
5.4.2	Identi	ty of Clinical Supplies	45
5.	4.2.1 I	RotaTeq [™] at Expiry Potency and Placebo	45
5.	4.2.2 1	Development of Clinical Materials	48
5.4.3	Metho Group	od of Assigning Subjects to Treatment	50
5.4.4	Select Dose	ion of Doses in the Study and Timing of for Each Subject	51
5.4.5	Study	Blinding	52
5.4.6	Prior a	and Concomitant Therapies	54
5.4.7	Treatn	nent Compliance	55
5.5 Eff Par	icacy, In ameters	nmunogenicity, Safety, and Tolerability	55
5.5.1	Measu Assess	arements Assessed and Timing of sment	55
5.	5.1.1 H	Efficacy Measurements	55
5.	5.1.2 I	mmunogenicity Measurements	58
	5.5.1.2	.1 Evaluation of Antibody Responses to RotaTeq [™]	58
5.	5.1.3 8	Safety Measurements	58
	5.5.1.3	.1 Monitoring for Adverse Experiences	58
	5.5.1.3	.2 Monitoring for Serious Adverse Experiences Including Intussusception	59
	5.5.1.3	.3 Fecal Rotavirus Vaccine Virus Shedding	61

CSR SYNOPSIS (CONT.) Protocol 007

-2-

V260

Rotavirus Vaccine, Live, Oral, Pentavalent

DOSAGE/FORMULATION NOS.:

- **Regimen:** Three (3) doses of the clinical material were administered to each subject orally. The volume of each vaccination was 2.0 mL of vaccine or placebo. Vaccination 1 was to be administered on Day 1, Vaccination 2 was to be administered 28 to 70 days after Vaccination 1, and Vaccination 3 was to be administered 28 to 70 days after Vaccination 2.
- **Clinical Material:** RotaTeqTM at expiry potency (Lot Nos. V260 VAO 0190001 and V260 VAO 0190002) contained approximately ^(b) ⁽⁴⁾mg of sucrose, approximately ^(b) ⁽⁴⁾mg of sodium citrate, approximately ^(b) ⁽⁴⁾mg of sodium phosphate, ^(b) ^(b) ^(c) mL of tissue culture medium, and no greater than ^(b) ⁽⁴⁾mg of polysorbate-80, and human-bovine rotavirus reassortants G1, G2, G3, G4, and P1 with an estimated final aggregate potency of ~1.1 x10⁷ infectious units (IU)/dose in approximately 2.0 mL of buffer/stabilizer. Theoretical calculation of ^(b) ⁽⁴⁾ material ^(b) ⁽⁴⁾ was ^(b) ug/dose. Trace components of fetal bovine serum may have also been present.

DIAGNOSIS/INCLUSION CRITERIA: Healthy infants, 6 through 12 weeks of age, who had no known history of congenital abdominal disorders, intussusception, or abdominal surgery; no known or suspected impairment of immunological function; no known hypersensitivity to any component of the rotavirus vaccine; no prior receipt of any rotavirus vaccine; no fever, with a rectal temperature ≥38.1°C (≥100.5°F) at the time of immunization; no history of known prior rotavirus disease, chronic diarrhea, or failure to thrive; no clinical evidence of active gastrointestinal illness. (Note that infants with gastroesophageal reflux disease [GERD] were permitted to participate in the study as long as the GERD was well controlled with or without medication.); no receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 2 weeks prior to vaccination; did not reside in a household with an immunoglobulins; no receipt of oral poliovirus vaccine (OPV) during the course of the study or within 42 days prior to the first dose of vaccine/placebo; any infant who could not be adequately followed for safety by telephone or home visit; and no condition, which, in the opinion of the investigator, may have interfered with the evaluation of the study objectives.

EVALUATION CRITERIA:

- Efficacy: The case definition for rotavirus gastroenteritis required subjects to meet both of the following criteria: (1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and (2) Rotavirus detected by enzyme immunoassay (EIA) in a stool specimen taken within 14 days after the onset of symptoms. All rotavirus-positive stools were evaluated for serotype identification by polymerase chain reaction (PCR). Only naturally-occurring rotavirus AGEs caused by the human rotavirus G- serotypes in the vaccine were included in the primary analysis.
- **Immunogenicity:** In a subset of approximately 175 subjects, antibody responses to the vaccine were evaluated by several assays. Serum samples were collected before Dose 1 and approximately 42 days after Dose 3. Serum was tested by modified enzyme-linked immunosorbent assay (ELISA) for serum neutralizing antibodies (SNA) against the rotavirus serotypes contained within the vaccine (G1, G2, G3, G4, P1, and WC3 (the WC3 serotype is also characterized as G6 and P7[5] throughout this document)). Serum anti-rotavirus IgA was also evaluated.
- **Safety:** The subjects' parent/legal guardians were asked to record any adverse experiences that occurred within 42 days following any vaccination. The subjects' parent/legal guardians were instructed to record daily for the first 7 days following vaccination the subject's temperature, behavioral changes, and the number of episodes of vomiting and/or diarrhea.

-9-

5.4.2 Identity of Clinical Supplies

5.4.2.1 RotaTeqTM at Expiry Potency and Placebo

The placebo was approximately 2.0 mL per dose that contained approximately (b) (4) mg of sucrose, approximately (4) mg of sodium citrate, approximately (b) (4) mg of sodium phosphate, and no greater than (b) (4) mg of polysorbate-80.

Vaccine was provided in kits. Each kit was intended for a single subject and contained 3 doses of vaccine/placebo. The kits were labeled with at least the following information: Rotavirus Vaccine/Placebo, 3 vials each containing 2.0-mL dose for oral administration, store at 2 to 8°C, AN, protocol number, packaging control number (WP-XXXX (control number pertained to shipments that included both vaccine and placebo)), SPONSOR name and address, and applicable caution statements and any additional country-specific label requirements.

Two (2) mL of vaccine or placebo were drawn up from the vial using a syringe. The needle was removed from the syringe and the vaccine was dispensed orally to the infant.

Once labeled, RotaTeqTM at expiry potency was indistinguishable from the placebo. Thus, upon arrival at the clinical study site, the treatment contained within each vial was blinded to the investigator, the subject, and the parent/legal guardian.

23-Dec-2004

.

LIST OF APPENDICES (CONT.)

<u> </u>	Appendix	Application Starting Page
CATEGORY 2:	REPORTS	
2.1	MRL or Other Clinical Study Reports (Synopses)	
2.1,1	MRL Clinical Study Report (Synopsis): Safety, Tolerability, and Immunogenicity of Live Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine in Healthy Adults (Protocol 001).	441
2.1.2	MRL Clinical Study Report (Synopsis), Multicenter Study: Safety, Immunogenicity, and Efficacy of a Live, Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine in Healthy Infants (Protocol 002).	444
2.1.3	MRL Clinical Study Report (Synopsis), Multicenter Study: Safety, Immunogenicity, and Efficacy in Healthy Infants of G1 and G2 Human-Bovine Rotavirus Reassortant Vaccine in a New Buffer/Stabilizer Liquid Formulation (Protocol 003).	449
2.1,4	MRL Clinical Study Report (Synopsis), Multicenter Study: Safety and Tolerability of Oral, Live G4 Human- Bovine Reassortant Rotavirus Vaccine in Healthy Adults and Healthy Infants (Protocol 004).	455
2.1.5	MRL Clinical Study Report (Synopsis): Safety, Immunogenicity, and Efficacy in Healthy Infants of G1, G2, G3, G4, and P1 Human-Bovine Rotavirus Reassortant Vaccine (Protocol 005).	459
CATEGORY 3:	STUDY DOCUMENTS	
3.1	Principal Authors' and Investigator's Signatures	467
3.2	Audit Information Sheet	469
3.3	Protocol and Protocol Amendment(s)Including Sample Consent Form	
3.3.1	Protocol 007-00	470
3.3.2	Protocol Amendment 007-01	539
3.3.3	Protocol Amendment 007-02	614
3.4	Protocol-Specific Informed Consent	
3.4.1	Main Generic Informed Consent Form	691

CLINICAL STUDY REPORT I. SYNOPSIS

V260

Live Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine for Oral Administration

Quadrivalent Vaccine Containing Serotypes G1, G2, G3, and P1

PROTOCOL TITLE/NO.: Safe	ty, Tolerability, and	Immunogenicity of Live #001						
Quadrivalent Human-Bovine Rotavir	us Reassortant Vaccine	e in Healthy Adults						
INVESTIGATOR(S)/STUDY CENTER(S): Paul A. Offit, M.D., Philadelphia, PA, U.S.A.								
PRIMARY THERAPY PERIOD: 1	9-Jun-1993 to 08-Jul-19	993; CLINICAL PHASE: I						
Clinical Data Cutoff Date: 04-D	Clinical Data Cutoff Date: 04-Dec-1996; Serology Cutoff							
Date: 11-Nov-1996; Study Completi	on Date: 08-Jul-1993.							
DURATION OF TREATMENT: S	Single dose/14-day follo	ow-up.						
OBJECTIVE(S): Primary Objectiv	e: To determine if the	e vaccine is safe in healthy immune adults.						
Secondary Objective: To investiga	te immune responses :	after a single dose of quadrivalent vaccine						
when administered orally to healthy a	adults.							
STUDY DESIGN: Double-blind, rat	ndomized, placebo-con	trolled trial.						
SUBJECT ACCOUNTING:								
	Rotavirus Vaccine	Placebo						
ENTERED: Total	20							
Male (age range-years)	10 (22 to 40)	5 (21 to 42)						
Female (age range-years)	10 (19 to 47)	6 (22 to 34)						
COMPLETED:	19	11						
DISCONTINUED: Total	1	0						
Clinical adverse experience	0	0						
Laboratory adverse experiences	0	0						
Refused further participation	1	0						

DOSAGE/FORMULATION NOS.: Regimen: A 1.0-mL dose of vaccine/placebo orally administered, following an 8-hour overnight fast. One-half hour before administration, subjects were given 4 teaspoons of MAALOX[™] (magnesia alumina oral suspension antacid, Novartis Consumer Health, Inc.) to ensure uniform gastric buffering and were asked to refrain from eating for 1 hour after administration of vaccine/placebo. Clinical Material: Quadrivalent human-bovine rotavirus reassortant vaccine, Lot 1340A/C-Y560A, 1.2-mL vial. This vaccine contained serotypes G1, G2, G3, and P1 each with an estimated final titer of 1 x 10⁷ plaque-forming units (PFU)/mL in (b)(4) Medium (b)(4)(b) (4) with (b) (4) at (b) (4) at (b) (4) at (b) (4) at (b) (4) . Placebo, Lot 1341/C-Y561, 1.2-mL vial. This placebo contained (b) (4) Medium (b) (4) with (b) (4) (b) (4) at (b) (4) and (b) (4) at (b) (4) at

DIAGNOSIS/INCLUSION CRITERIA: Healthy adults 18 years of age or older who had no: known hypersensitivity to any component of the rotavirus vaccine, e.g., (b) (4); known or suspected impairment of immunologic function; fever, $\geq 100^{\circ}$ F (oral) at the time of immunization; clinical evidence of chronic or active gastrointestinal illness prior to immunization; other vaccines given within 14 days prior to administration of study vaccine; history of drug or alcohol abuse. Subjects were not pregnant or expecting to conceive during the study period. Subjects must have agreed to use an acceptable method of birth control for 2 weeks after the immunization. Abstinence was considered an acceptable method of birth control. Subjects did not have any condition which, in the opinion of the investigator, might have interfered with the evaluation of the study objectives.

EVALUATION CRITERIA: Immunogenicity Evaluation: Serum neutralizing antibody levels (for each of G1, G2, G3, P1, bovine WC3 strain, and human W179 strain specificities). Safety Evaluation: Incidence of serious vaccine-related adverse experiences (Days 0 to 14 postvaccination); fecal vaccine virus shedding (Days 2 to 7 postvaccination); temperature elevations (Days 0 to 14 postvaccination); and serum alanine transaminase (ALT) levels (Days 0 and 14 postvaccination).

BC1421.DOC VERSION 21.1 APPROVED

Restricted @ Confidential - Limited Access

09-Feb-2004

V260

Live Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine. Oral Rotavirus Gastroenteritis

CSR SYNOPSIS (CONT.) Protocol 002

-2-

DOSAGE/FORMULATION NOS.:

Regimen: Three (3) doses of the clinical material were administered to each subject orally. The volume of each dose was 1.0 mL of quadrivalent G1, G2, G3, and P1 human-bovine reassortant rotavirus vaccine or placebo. Dose 1 was given on Day 0, Dose 2 was given 6 to 8 weeks after Dose 1, and Dose 3 was given 6 to 8 weeks after Dose 2.

CLINICAL MATERIAL:

			Potency	
Vaccine	Lot Number-Fill Number	Dosage	(PFU/dose)	Package
Live rotavirus vaccine	1340A/C-Y560A	1.0 mL	4×10^7	Code-labeled vial kept at
Diasaha	1241/C X561	1.0 mJ	0	(b) (4) Code lokeled viel least et
riacebo	1341/C-1301	1.0 IIIL	0	(b) (4)

DIAGNOSIS/INCLUSION CRITERIA: Healthy infants, 2 to 6 months of age who had no known or suspected impairment of immunologic function; no prior administration of any rotavirus vaccine; no fever (defined as a rectal temperature of ≥100.4°F) at the time of immunization; no history of chronic diarrhea or failure to thrive; no clinical evidence of active gastrointestinal disease; no other vaccines given within (+/-) 14 days of any dose of vaccine; no condition that, in the opinion of the investigator, could have interfered with the evaluation of the study objectives; and no infant who resided in a household with an immunocompromised individual.

EVALUATION CRITERIA: <u>Efficacy</u>: The case definition for rotavirus gastroenteritis was that a subject must have met both of the following criteria: $(1) \ge 3$ watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting. (2) Rotavirus must have been identified in a stool specimen taken within 14 days of the onset of symptoms. <u>Immunogenicity</u>: Serum samples, taken Predose 1 and Postdose 3, were tested by enzyme immunoassay (EIA) for serum neutralizing antibody (SNA) against G1, G2, G3, P1a, P1G1, G6, and P7. Serum was also tested for anti-rotavirus IgA and IgG. Stool samples, taken Predose 1 and Postdose 3, were tested to record any adverse experiences that occurred within 14 days after any vaccination. Temperatures were recorded daily for 7 days after each administration of vaccine/placebo. Stool samples for viral shedding were obtained from all participants between Day 3 and Day 5 after Dose 1. In addition, the Philadelphia study site collected stool samples for vaccine viral shedding 1 to 2, 3 to 5, 7 to 9, and ~15 days following each dose.

STATISTICAL PLANNING AND ANALYSIS:

Efficacy: The primary efficacy hypothesis that the quadrivalent rotavirus vaccine provides efficacy against rotavirus disease throughout one rotavirus season was tested using an exact conditional procedure. The primary hypothesis in the protocol refers to 80% efficacy, which is the expected efficacy that was used for power and sample size calculations; however, the primary hypothesis was tested for vaccine efficacy >0.0% relative to placebo, as noted in the Data Analysis Plan (DAP). A point estimate and exact two-sided 95% confidence interval for vaccine efficacy were also calculated. In order for the quadrivalent rotavirus vaccine to be declared efficacious (i.e., in order to reject the null hypothesis), the lower bound on the confidence interval for vaccine efficacy had to exceed 0%. If there were 160 evaluable infants per group, and assuming that the true incidence of disease in the placebo group would be 10% and that the vaccine would be 80% efficacious in the prevention of rotavirus disease, there would be 80% power to reject the primary null hypothesis. One hundred eighty (180) evaluable infants per group.

BC3418.DOC VERSION 18.0 APPROVED

Restricted Confidential – Limited Access

09-Dec-2003

V260 G1 G2 Reassortant Rotavirus **CSR SYNOPSIS (CONT.)** Protocol 003

-2-

Vaccine Live (Human-Bovine)	
Oral	
Rotavirus Gastroenteritis	
SUBJECT ACCOUNTING:	

Sebuler Accounting.							
	Rotavirus (G1, G2) Vaccine				Placebo		
	1.0 mL – No Buffer (Group 1)	1.0 mL – 1x Buffer (Group 3)	2.5 mL – 1x Buffer (Group 5)	1.0 mL – Conc. Buffer (Group 7)	(Groups 2, 4, 6, and 8 Combined)		
ENTERED: Total	142	150	147	142	150		
Male (age range—weeks)	64 (8 to 21)	74 (8 to 21)	76 (6 to 21)	77 (8 to 21)	79 (8 to 21)		
Female (age range-weeks)	78 (6 to 21)	76 (8 to 21)	71 (7 to 21)	65 (8 to 21)	71 (8 to 21)		
COMPLETED:	136	138	137	132	138		
DISCONTINUED: Total	6	12	10	10	12		
Clinical adverse experience	0	1	0	2	2		
Refused further participation	3	6	6	5	6		
Lost to follow-up	3	5	4	3	4		

DOSAGE/FORMULATION NOS.: Regimen: Three (3) doses of the clinical material were administered to each subject orally. The volume of administration was either 1.0 mL or 2.5 mL, depending upon the subject's group assignment. Each dose was provided under the following schedule: Dose 1, given on Day 0.

Dose 2, given between Days 42 and 56.

Dose 3, given between Days 84 and 98.

Group	Prefeeding	Vaccine Vol (mL)	Buffer/Stabilizer	PFU/Dose
1	Yes	1.0	None	1x 10 ⁷ PFU
2^{\dagger}	Yes	1.0	None	0
3	No	1.0	1x	1x 10 ⁷ PFU
4^{\dagger}	No	1.0	1x	0
5	No	2.5	1x	1x 10 ⁷ PFU
6^{\dagger}	No	2.5	1x	0
7	No	1.0	Concentrate	1x 10 ⁷ PFU
8†	No	1.0	Concentrate	0
[†] Placebo.				

CLINICAL MATERIAL: G1 and G2 human-bovine reassortant rotavirus vaccine, a live virus vaccine, Lots No. 1507/W-D152, 1493/W-C971, 1494/W-C972, and 1495/W-C973. The vaccine contained serotypes G1 and G2, each with an estimated final titer of 5 x 10^6 PFU/reassortant or a total of 1×10^7 PFU G1 and G2 human-bovine rotavirus reassortant vaccine per dose, in (b) (4) Medium (b) (4) (b) (4) Placebo represented buffer alone; i.e., without rotavirus vaccine, Lots No. 1506/W-D151, 1489/W-C967, 1490/W-C968, and 1491/W-C969.

BC3684.DOC VERSION 9.1 APPROVED

Restricted Sconfidential - Limited Access

10-Sep-2003

CLINICAL STUDY REPORT I. SYNOPSIS

V260 G4 Human-Bovine Reassortant Rotavirus Vaccine, Oral

Rotavirus Vaccine, Oral Rotavirus gastroenteritis

PROTOCOL TITLE/NO.: Safety and Tolerability of Oral, Live	G4 Human-Bovine	#004			
Reassortant Rotavirus Vaccine in Healthy Adults and Healthy Infants					
INVESTIGATOR(S)/STUDY CENTER(S): Multicenter (02) U.S.					
PRIMARY THERAPY PERIOD: 19-Mar-1998 to 07-Jul-1998	CLINICAL PHASE:	IIb			
(last dose of therapy).					
Study completed: 18-Aug-1998.					
Clinical Case Report Form and Laboratory Data In-House Cut-off					
Date: 10-Sep-1999.					
DURATION OF TREATMENT: Single dose/42-day follow-up.					
OD IECTIVE(S). To serve that the CA	11	1			

OBJECTIVE(S): To assess that the G4-reassortant rotavirus vaccine is generally safe and well tolerated, in order to include it in a multivalent oral live rotavirus vaccine.

STUDY DESIGN: Double-blinded, placebo-controlled randomized study organized in 2 stages. Stage 1 was conducted in healthy adults; Stage 2 was conducted in healthy infants, after subjects from Stage 1 had been followed 14 days without any vaccine-related serious adverse experiences. Within each stage, subjects were randomized between vaccine and placebo groups at a ratio of 2:1.

SUBJECT ACCOUNTING:

	Adults			Infants			
	(A	ge Range in Yea	rs)	(A	ge Range in Week	(S)	
				Rotavirus			
	Rotavirus			(G4 Vaccine)			
	(G4 Vaccine)	Placebo	Total	Vaccine	Placebo	Total	
ENTERED: Total	10	5	15	47	23	70	
Male (age range)	6 (26 to 53)	3 (23 to 30)	9 (23 to 53)	25 (8 to 21)	13 (9 to 21)	38 (8 to 21)	
Female (age range)	4 (27 to 54)	2 (28 to 32)	6 (27 to 54)	22 (9 to 21)	10 (8 to 21)	32 (8 to 21)	
COMPLETED:	10	5	15	46	22	68	
DISCONTINUED: Total	0	0	0	1	1	2	
Clinical adverse experience	0	0	0	0	0	0	
Deviation from protocol	0	0	0	0	0	0	
Refused further participation	0	0	0	0	0	0	
Lost to follow-up	0	0	0	1	1	2	

DOSAGE/FORMULATION NOS.:

Regimen: A single, 1-mL dose of clinical material, vaccine or placebo, was administered orally to each subject on Day 0. The vaccine was given approximately one-half hour after the administration of a buffering agent.

C	<u>linical Trial Material</u>	: The vaccine	contained G	4 human-b	ovine reass	ortant rotavi	irus with an	estimated
	final titer of 10 ⁷ pla	aque-forming u	inits (PFU)	in a 1-mL	dose. Th	ne vaccine	composition	included
	(b) (4) Medium	(b) (4		at	(b) (4)	at	(b) (4)	at
	(b) (4) , and su	crose	(b) (4)		Lot No.	V260-OS0	D-001-D0 01	. Trace
	components of fetal	bovine serum	may also h	ave been	present in	the vaccine	e. The pla	cebo was
	composed of (b) (4)	Medium	(b) (4)		at	(b) (4)	at (p)	(4) and
	Sucrose (t	o) (4)	, Lot No. 1	506/W-D1	51.			

E. STUDY DESIGN (CONT.)

If immediately following any dose of RotaTeqTM/placebo, a subject develops a SAE that is judged by the investigator to be related to vaccination, the subject should not receive any additional doses; however, they should continue to be followed for safety.

A masked allocation schedule will be provided to a pre-designated Merck clinical monitor, a pre-designated Merck subsidiary personnel and a predesignated CRO personnel. This masked allocation schedule should be used ONLY if unblinding is approved by the Merck clinical monitor and is absolutely essential for the welfare of the subject. It is also important to remember that for potential cases of intussusception, it is desirable to remain blinded to the treatment arm given that intussusception is the primary safety endpoint of another concurrently enrolling study, which is being monitored by a DSMB.

Description of RotaTeqTM and Placebo: Both RotaTeqTM and the placebo contain ~2 mL of a buffered liquid consisting of ^[b] g sucrose, ^{(b) (4)} citrate, ^{(b) (4)} phosphate, ^(b) mL tissue culture medium, and no greater than ^(b) mg polysorbate 80. RotaTeqTM also contains human-bovine reassortants G1, G2, G3, G4, and P1 with an estimated final dose of 1.0 x 10⁷ total Infectious Units², and ^{(b) (4)}. Trace amounts of fetal bovine serum may also be present.

b. Special Handling Requirements

Vials of RotaTeqTM and placebo will be shipped to the study sites frozen on dry ice. The vaccine and placebo will be indistinguishable, with ~2.5 mL of material in a 6 mL vial. The RotaTeqTM/placebo should be placed in the refrigerator at $\binom{10}{44}$ to 8°C immediately after arrival, and should be stored refrigerated until needed for administration. A refrigerator temperature log must be maintained at the site. The log will be reviewed throughout the course of the study by the site field monitors. Refrigerator temperatures of $\binom{(b)}{4}$ to 8°C are acceptable for storage of RotaTeqTM/placebo. If the refrigerator temperator temperator

² Infectious units are used to designate the potency values generated in the novel M-QPA potency assay. The assay enumerates the accumulation of viral nucleic acid following a productive infection and relates it to a reference standard of known potency. This is a Merck & Co., Inc. specific assay.

E. STUDY DESIGN (CONT.)

A masked allocation schedule will be provided to a predesignated Merck clinical monitor, a predesignated Merck subsidiary personnel and a predesignated CRO personnel. This masked allocation schedule should be used ONLY if unblinding is approved by the Merck clinical monitor and is absolutely essential for the welfare of the subject. It is also important to remember that for potential cases of intussusception, it is desirable to remain blinded to the treatment arm given that intussusception is the primary safety endpoint of another concurrently enrolling study, which is being monitored by a DSMB.

Description of RotaTeq[™] and Placebo: Both RotaTeq[™] and the placebo contain ~2 mL of a buffered liquid consisting of g sucrose, (5)(4) citrate, (b) (4) phosphate, $\binom{(b)}{(4)}$ mL tissue culture medium, and no greater than $\binom{(b)}{(4)}$ mg polysorbate 80. RotaTeq[™] also contains human-bovine reassortants G1, G2, G3, G4, and P1 with an estimated final dose of 1.0×10^7 total Infectious Units. (b) (4) . Trace amounts of fetal bovine serum and may also be present.

b. Special Handling Requirements

Vials of RotaTeq[™] and placebo will be shipped to the study sites frozen on dry ice. The vaccine and placebo will be indistinguishable, with ~2.5 mL of material in a 6 mL vial. The RotaTegTM/placebo should be placed in the refrigerator at to 8°C immediately after arrival, and should be stored refrigerated until needed for administration. A refrigerator temperature log must be maintained at the site. The log will be reviewed throughout the course of the study by the site field monitors. Refrigerator temperatures of

^{(b) (4)} to 8°C are acceptable for storage of RotaTeqTM/placebo. If the refrigerator (b) (4) temperature moves outside of this range or above 8°C [46.4°F]), the SPONSOR should be notified and the vaccine should not be used.

If a vial is needed for administration and is still frozen, it should be thawed by letting it stand at room temperature for 30 minutes. Thawing may be initiated by warming with gloved hands; however, it is recommended that hand warming end when thawing approaches completion and a small amount of frozen material is still visible. RotaTeqTM/placebo should be administered within 30 minutes of thawing. In the event a vial has been mishandled and cannot be used (e.g., it is not given within 30 minutes of thawing), study personnel should contact the appropriate MPC.

07-Apr-2003

E. <u>STUDY DESIGN</u> (CONT.)

A masked allocation schedule will be provided to a predesignated Merck clinical monitor, a predesignated Merck subsidiary personnel and a predesignated CRO personnel. This masked allocation schedule should be used ONLY if unblinding is approved by the Merck clinical monitor and is absolutely essential for the welfare of the subject. It is also important to remember that for potential cases of intussusception, it is desirable to remain blinded to the treatment arm given that intussusception is the primary safety endpoint of another concurrently enrolling study, which is being monitored by a DSMB.

Description of RotaTeqTM and Placebo: Both RotaTeqTM and the placebo contain ~2 mL of a buffered liquid consisting of $\begin{bmatrix} 15\\ (4) \end{bmatrix}$ g sucrose, $\begin{bmatrix} (5) & (4) \end{bmatrix}$ citrate, $\begin{bmatrix} (5) & (4) \\ (4) \end{bmatrix}$ phosphate, $\begin{bmatrix} (5) & mL \\ (4) \end{bmatrix}$ mL tissue culture medium, and no greater than $\begin{bmatrix} (5) & (4) \\ (4) \end{bmatrix}$ mg polysorbate 80. RotaTeqTM also contains human-bovine reassortants G1, G2, G3, G4, and P1 with an estimated final dose of 1.0×10^7 total Infectious Units, and $\begin{bmatrix} (b) & (4) \\ (4) \end{bmatrix}$. Trace amounts of fetal bovine serum may also be present.

b. Special Handling Requirements

Vials of RotaTeqTM and placebo will be shipped to the study sites frozen on dry ice. The vaccine and placebo will be indistinguishable, with ~2.5 mL of material in a 6 mL vial. The RotaTeqTM/placebo should be placed in the refrigerator at to 8°C immediately after arrival, and should be stored refrigerated until needed for administration. A refrigerator temperature log must be maintained at the site. The log will be reviewed throughout the course of the study by the site field monitors. Refrigerator temperatures of

(b) (4) to 8°C are acceptable for storage of RotaTeqTM/placebo. If the refrigerator temperature moves outside of this range (b) (4) or above 8°C [46.4°F]), the SPONSOR should be notified and the vaccine should not be used.

If a vial is needed for administration and is still frozen, it should be thawed by letting it stand at room temperature for 30 minutes. Thawing may be initiated by warming with gloved hands; however, it is recommended that hand warming end when thawing approaches completion and a small amount of frozen material is still visible. RotaTeqTM/placebo should be administered within 30 minutes of thawing. In the event a vial has been mishandled and cannot be used (e.g., it is not given within 30 minutes of thawing), study personnel should contact the appropriate MPC.

18-Sep-2003

Reference P009

MRL Clinical Study Report, Multicenter Study: Comparison of the Immunogenicity and Safety of Three Consistency Lots of RotaTeq[™] in Healthy Infants (Protocol 009)

CLINICAL STUDY REPORT

Comparison of the Immunogenicity and Safety of Three Consistency Lots of RotaTeq[™] in Healthy Infants (Protocol 009)

TABLE OF CONTENTS

				Application Starting Page
I.	SYI	NOPS	IS	19
II.	CO	24		
	1.	Intro	oduction	24
	2. Ethics		cs	30
		2.1	Ethics Review Committee/Independent Ethics Committee/Institutional Review Board	30
		2.2	Ethical Conduct of the Study	30
		2.3	Subject Information and Informed Consent Form	31
	3.	Inve	estigators and Study Administrative Structure	32
		3.1	Investigators	32
		3.2	Independent Committees for the Assessment of Safety	32
		3.3	Laboratories	33
		3.4	Authors of Clinical Study Report (CSR)	33
		3.5	Additional Vendors	33
	4.	Stuc	ly Hypotheses and Objectives	34
		4.1	Hypotheses	34
		4	1.1.1 Primary Hypotheses	34
		4.2	Objectives	34
		4	2.1 Primary Objectives	34
		4	2.2. Secondary Objectives	34
	5.	Inve	estigational Plan	35
		5.1	Overall Study Design and Plan: Description	35
		5.2	Discussion of Study Design, Including the Choice of Control Groups	39

TABLE OF CONTENTS (CONT.)

				Applic Star Pa	ation ting ge
5.3	Sele	ection of S	tudy Population		39
	5.3.1	Inclusion	Criteria		39
	5.3.2	Exclusion	n Criteria		40
	5.3.3	Discontir Study Ob	nuation of Subjects From Therapy or osservation		41
5.4	Trea	atments			41
	5.4.1	Treatmen	ts Administered		41
	5.4.2	Identity of	of Clinical Supplies		41
	5.4	4.2.1 Rot	aTeq [™] and Placebo		4 1
	5.4	4.2.2 Dev	elopment of Clinical Materials		43
	5.4.3	Method of Groups	of Assigning Subjects to Treatment		46
	5.4.4	Selection Dose for	of Doses in the Study and Timing of Each Subject		47
	5.4.5	Study Bl	inding		48
	5.4.6	Prior and	Concomitant Therapies		50
	5.4.7	Treatmen	t Compliance		51
5.5	Imn	nunogenici	ty and Safety Parameters		51
	5.5.1	Measurer Assessme	nents Assessed and Timing of ent		51
	5.5	5.1.1 Imn	nunogenicity Measurement		51
		5.5.1.1.1	Evaluation of Antibody Response to RotaTeq [™]		52
	5.5	5.1.2 Safe	ety Measurement		52
		5.5.1.2.1	Monitoring for Adverse Experiences		52
		5.5.1.2.2	Monitoring for Serious Adverse Experiences Including Intussusception		53
5.6	Data	a Quality A	Assurance		54
5.7	Stat	istical Met ermination	hods Planned in the Protocol and of Sample Size		55
	5.7.1	Statistica Objective	l and Analytical Plans to Address Study		55

CSR SYNOPSIS (CONT.) Protocol 009

V260 Rotavirus Vaccine, Live, Oral, Pentavalent

-2-

DOSAGE/FORMULATION NOS.:

Regimen: Three (3) doses of the clinical material were to be administered to each subject orally. The volume of each vaccination was approximately 2.0 mL of vaccine or placebo. Vaccination 1 was administered on Day 1, Vaccination 2 was to be administered 28 to 70 days after Vaccination 1, and Vaccination 3 was to be administered 28 to 70 days after Vaccination 2.

Clinical Material: RotaTeqTM (Lot 1 No.: V260 VAO 020 R001; Lot 2 No.: V260 VAO 020 R002; and Lot 3 No.: V260 VAO 020 R003) was approximately 2.0 mL per dose that contained approximately 10^{10} mg of sucrose, approximately 10^{10} mg of sodium citrate, approximately 10^{10} mg of polysorbate 80, and human-bovine rotavirus reassortants G1, G2, G3, G4, and P1 in approximately 2.0 mL of buffer/stabilizer with a measured aggregate potency of 8.81 X 10⁷ Infectious Units (IU)/dose, 8.01 X 10⁷ IU/dose, and 6.91 X 10⁷ IU/dose for Lot 1, Lot 2, and Lot 3, respectively.

The placebo (Lot No. PV260 VAO 022 P001) was approximately 2.0 mL per dose that contained approximately ¹⁰¹⁴⁴ ng of sucrose, approximately ¹⁰¹⁴⁶ ng of sodium citrate, approximately ¹⁰¹⁴⁶ ng of sodium phosphate ⁽⁵⁾ mL of tissue culture medium, and no greater than ¹⁰/₂, mg of polysorbate 80.

DIAGNOSIS/INCLUSION CRITERIA: Healthy infants, 6 through 12 weeks of age, who had no known history of congenital abdominal disorders, intussusception, or abdominal surgery; no known or suspected impairment of immunological function; no known hypersensitivity to any component of the rotavirus vaccine; no prior receipt of any rotavirus vaccine; no fever, with a rectal temperature ≥38.1°C (≥100.5°F) at the time of immunization; no history of known prior rotavirus disease, chronic diarrhea, or failure to thrive; no clinical evidence of active gastrointestinal illness. (Note that infants with gastroesophageal reflux disease [GERD] were permitted to participate in the study as long as the GERD was well controlled with or without medication.); no receipt of a blood transfusion or blood products, including immunoglobulins; no receipt of oral poliovirus vaccine (OPV) during the course of the study or within 42 days prior to the first dose of vaccine/placebo; any infant who could not be adequately followed for safety by telephone or home visit; and no condition, which, in the opinion of the investigator, may have interfered with the evaluation of the study objectives.

EVALUATION CRITERIA:

Immunogenicity: Antibody responses (SNA Postdose 3 GMTs against rotavirus serotypes G1, G2, G3, G4, and P1 and serum anti-rotavirus IgA) to RotaTeqTM/placebo were evaluated in all subjects. These assays were performed on one serum sample collected from each subject approximately 42 days Postdose 3. In addition, Predose 1 serum samples were to be collected in a subset of approximately 140 subjects (approximately 40 subjects per vaccine lot and approximately 20 subjects in the placebo group) at predetermined study sites. Predose 1 serum samples were assayed for SNA against rotavirus serotypes G1, G2, G3, G4, and P1.

Safety: The subjects' parent/legal guardians were asked to record any adverse experiences that occurred within 42 days following any vaccination. The subjects' parent/legal guardians were instructed to record daily for the first 7 days following vaccination the subject's temperature, behavioral changes, and the number of episodes of vomiting and diarrhea.

5.3.3 Discontinuation of Subjects From Therapy or Study Observation

A subject was considered to have completed the study when he/she had at least: (1) Received all 3 scheduled vaccinations; and (2) Completed at least 42 days of safety follow-up after each vaccination. Reasons for premature withdrawal from the study were recorded on the worksheets [3.5].

5.4 <u>Treatments</u>

5.4.1 Treatments Administered

The protocol designated 4 treatment group assignments, 1 group for each of the 3 lots of RotaTeqTM and 1 group for placebo. Table 5-3 (Section 5.4.2.1) summarizes the dosage and potency administered to subjects enrolled in each treatment group.

The protocol directed that each subject receive 3 oral doses of RotaTeqTM or placebo administered in 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart (dose intervals were calculated based on date of dose = Day 1). The first dose was administered between 42 and 84 days of age (age was calculated based upon date of birth = Day 1). The formulation of vaccine used in this study did not require prefeeding the subject prior to administration.

5.4.2 Identity of Clinical Supplies

5.4.2.1 RotaTeqTM and Placebo

Each dose of RotaTeq[™] contained human-bovine rotavirus reassortants G1, G2, G3, G4, and P1 and was supplied at a potency within the range of the final release potencies, in the final formulation, and in the final container intended for the licensed product. Placebo was supplied in an identical container. The estimated final volume/dose of RotaTeqTM was approximately 2 mL, and the infectious units (IU)/reassortant/dose to potency range was (D) (2) IU/reassortant/dose, IU/dose. The potency for each of the consistency lots was targeted for the middle of the range; the actual potencies ranged from 6.91 x 10^7 IU/dose to 8.81 x 10' IU/dose. The potencies of the 3 lots of RotaTeq[™] were measured using a multivalent quantitative polymerase chain reaction assay (M-QPA) which measures the potency of each reassortant serotype. The total potency/dose is calculated as the sum of the potencies of each of the individual reassortants. A description of this assay can be found in Section II.11.4. The vaccine was a buffered, liquid product that was ideally stored at 2 to 8°C. The formulation

42

-8-

used in this study, when fully characterized, contained approximately $\stackrel{(b)}{}_{i4}$ mg of sucrose, approximately $\stackrel{(b)}{}_{i4}$ mg of sodium citrate, approximately $\stackrel{(b)}{}_{i4}$ mg of sodium phosphate, $\stackrel{(D)}{}_{i4}$ mL of tissue culture medium, and no greater than $\stackrel{(b)}{}_{i4}$ mg of polysorbate 80. Theoretical calculation of $\stackrel{(b)}{}_{i4}$ (b) (4) material $\stackrel{(b)}{}_{i4}$ (4) mg was $\stackrel{(b)}{}_{i4}$ mg/dose. Trace components of fetal bovine serum may also have been present.

Each dose of placebo was approximately 2 mL in volume, consisting of approximately $\binom{(b)}{(4)}$ mg of sucrose, approximately $\binom{(b)}{(4)}$ mg of sodium citrate, approximately $\binom{(b)}{(4)}$ mg of sodium phosphate $\binom{(b)}{(4)}$ mL of tissue culture medium, and no greater than $\binom{(b)}{(4)}$ mg of polysorbate 80

RotaTeqTM and placebo were supplied in the final container representative of that intended for the marketed product, which was packaged in a foil pouch. This container consisted of a plastic dosing tube with a twist-off cap, allowing for direct oral administration to the infant. The pouch containing the tube was labeled with double-panel blinded labels and contained information similar to the following: control number (control number pertained to shipments that included both vaccine and placebo), AN, storage conditions, dosage instructions "Administer as per Protocol" and cautionary statements, as applicable.

RotaTeqTM and placebo were provided in kits. Each kit was intended for a single subject and contained 3 doses of RotaTeqTM/placebo. The kits were labeled with at least the following information: RotaTeqTM Vaccine/Placebo, 3 tubes each containing ~ 2 mL dose for oral administration, store at 2 to 8°C, AN, protocol number, packaging control number (WP-XXXX), SPONSOR name and address, and applicable caution statements.

Once labeled, RotaTeqTM was indistinguishable from placebo. Thus, upon arrival at the clinical study site, the treatment contained in each kit was blinded to both the investigator and the subject.

Identity of the clinical materials is given in Table 5-3.

06-Jan-2005

LIST OF APPENDICES (CONT.)

Appendix	Starting Page
REPORTS	
MRL or Other Clinical Study Reports (Synopses)	
MRL Clinical Study Report (Synopsis): Safety, Tolerability, and Immunogenicity of Live Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine in Healthy Adults (Protocol 001).	429
MRL Clinical Study Report (Synopsis), Multicenter Study: Safety, Immunogenicity, and Efficacy of a Live, Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine in Healthy Infants (Protocol 002).	432
MRL Clinical Study Report (Synopsis), Multicenter Study: Safety, Immunogenicity, and Efficacy in Healthy Infants of G1 and G2 Human-Bovine Rotavirus Reassortant Vaccine in a New Buffer/Stabilizer Liquid Formulation (Protocol 003).	437
MRL Clinical Study Report (Synopsis), Multicenter Study: Safety and Tolerability of Oral, Live G4 Human- Bovine Reassortant Rotavirus Vaccine in Healthy Adults and Healthy Infants (Protocol 004).	443
MRL Clinical Study Report (Synopsis): Safety, Immunogenicity, and Efficacy in Healthy Infants of G1, G2, G3, G4, and P1 Human-Bovine Rotavirus Reassortant Vaccine (Protocol 005).	447
MRL Clinical Study Report (Synopsis), Multicenter Study: Study of the Efficacy, Safety, and Immunogenicity of RotaTeq [™] at Expiry Potency (Protocol 007).	455
STUDY DOCUMENTS	
Principal Authors' and Investigator's Signatures	461
Audit Information Sheet	463
Protocol and Protocol Amendment	
Protocol 009-00	464
Protocol Amendment 009-01	533
Protocol-Specific Informed Consent	
Vaccine Consent Form	604
	Appendix SEPORTS MRL or Other Clinical Study Reports (Synopses) MRL Clinical Study Report (Synopsis): Safety, Tolerability, and Immunogenicity of Live Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine in Healthy Adults (Protocol 001). MRL Clinical Study Report (Synopsis), Multicenter Study: Safety, Immunogenicity, and Efficacy of a Live, Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine in Healthy Infants (Protocol 002). MRL Clinical Study Report (Synopsis), Multicenter Study: Safety, Immunogenicity, and Efficacy in Healthy Infants of G1 and G2 Human-Bovine Rotavirus Reassortant Vaccine in a New Buffer/Stabilizer Liquid Formulation (Protocol 003). MRL Clinical Study Report (Synopsis), Multicenter Study: Safety and Tolerability of Oral, Live G4 Human-Bovine Reassortant Vaccine (Protocol 004). MRL Clinical Study Report (Synopsis): Safety, Mmunogenicity, and Efficacy in Healthy Infants of Aduts and Healthy Infants (Protocol 004). MRL Clinical Study Report (Synopsis), Multicenter Study: Study of the Efficacy, Safety, and Immunogenicity of RotaTeq TM at Expiry Potency (Protocol 007). MRL Clinical Study Report (Synopsis), Multicenter Study: Study of the Efficacy, Safety, a

CLINICAL STUDY REPORT I. SYNOPSIS

V260

Live Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine for Oral Administration Quadrivalent Vaccine Containing Serotypes G1, G2, G3, and P1

PROTOCOL TITLE/NO.: Safe	ety, Tolerability, and Ir	nmunogenicity of Live	#001
Quadrivalent Human-Bovine Rotav	irus Reassortant Vaccine in	Healthy Adults	
INVESTIGATOR(S)/STUDY CENT	TER(S): Paul A. Offit, M	I.D., Philadelphia, PA, U.S.A.	
PRIMARY THERAPY PERIOD:	19-Jun-1993 to 08-Jul-1993	; CLINICAL PHASE:	Ι
Clinical Data Cutoff Date: 04-1	Dec-1996; Serology Cutof	f	
Date: 11-Nov-1996; Study Comple	tion Date: 08-Jul-1993.		
DURATION OF TREATMENT:	Single dose/14-day follow-	up.	
OBJECTIVE(S): Primary Objecti	ve: To determine if the va	accine is safe in healthy immune	adults.
Secondary Objective: To investig	ate immune responses after	er a single dose of quadrivalent	vaccine
when administered orally to healthy	adults.		
STUDY DESIGN: Double-blind, r	andomized, placebo-control	led trial.	
SUBJECT ACCOUNTING:			
	Rotavirus Vaccine	Placebo	2
ENTERED: Total	20	11	
Male (age range-years)	10 (22 to 40)	5 (21 to 42)	
Female (age range-years)	10 (19 to 47)	6 (22 to 34)	
COMPLETED:	19	11	
DISCONTINUED: Total	1	0	
Clinical adverse experience	0	0	
Laboratory adverse experiences	0	0	
Refused further participation	1	0	
DOSAGE/FORMULATION NOS.:	Regimen: A 1.0-mL dose	e of vaccine/placebo orally admin	nistered,
following an 8-hour overnight f	ast. One-half hour befor	re administration, subjects were	e given

following an 8-hour overnight fast. One-half hour before administration, subjects were given 4 teaspoons of MAALOXTM (magnesia alumina oral suspension antacid, Novartis Consumer Health, Inc.) to ensure uniform gastric buffering and were asked to refrain from eating for 1 hour after administration of vaccine/placebo. <u>Clinical Material</u>: Quadrivalent human-bovine rotavirus reassortant vaccine, Lot 1340A/C-Y560A, 1.2-mL vial. This vaccine contained serotypes G1, G2, G3, and P1 each with an estimated final titer of 1 x 10⁷ plaque-forming units (PFU)/mL in ^{(b)(4)} Medium ^{(b)(4)}. Placebo, Lot 1341/C-Y561, 1.2-mL vial. This placebo contained ^{(b)(4)} and ^{(b)(4)} at

- DIAGNOSIS/INCLUSION CRITERIA: Healthy adults 18 years of age or older who had no: known hypersensitivity to any component of the rotavirus vaccine, e.g., (b) (4); known or suspected impairment of immunologic function; fever, ≥100°F (oral) at the time of immunization; clinical evidence of chronic or active gastrointestinal illness prior to immunization; other vaccines given within 14 days prior to administration of study vaccine; history of drug or alcohol abuse. Subjects were not pregnant or expecting to conceive during the study period. Subjects must have agreed to use an acceptable method of birth control for 2 weeks after the immunization. Abstinence was considered an acceptable method of birth control. Subjects did not have any condition which, in the opinion of the investigator, might have interfered with the evaluation of the study objectives.
- **EVALUATION CRITERIA:** Immunogenicity Evaluation: Serum neutralizing antibody levels (for each of G1, G2, G3, P1, bovine WC3 strain, and human W179 strain specificities). <u>Safety Evaluation</u>: Incidence of serious vaccine-related adverse experiences (Days 0 to 14 postvaccination); fecal vaccine virus shedding (Days 2 to 7 postvaccination); temperature elevations (Days 0 to 14 postvaccination); and serum alanine transaminase (ALT) levels (Days 0 and 14 postvaccination).

BC1421.DOC VERSION 21.1 APPROVED

Restricted Confidential – Limited Access

09-Feb-2004

V260

Live Quadrivalent Human-Bovine Rotavirus Reassortant Vaccine. Oral Rotavirus Gastroenteritis

CSR SYNOPSIS (CONT.) Protocol 002

-2-

DOSAGE/FORMULATION NOS.:

Regimen: Three (3) doses of the clinical material were administered to each subject orally. The volume of each dose was 1.0 mL of quadrivalent G1, G2, G3, and P1 human-bovine reassortant rotavirus vaccine or placebo. Dose 1 was given on Day 0, Dose 2 was given 6 to 8 weeks after Dose 1, and Dose 3 was given 6 to 8 weeks after Dose 2.

Clinical Trial Material: G1, G2, G3, and P1 serotype of human-bovine rotavirus reassortants, with an estimated final titer of 4 X 10^7 plaque-forming units (PFU), Lot No. 1340A/C-Y560A. Placebo represented buffer alone; i.e., without quadrivalent human-bovine rotavirus reassortants, Lot No. 1341/C-Y561. Vaccine and placebo contained (b) (4) Medium (b) (4) with (b) (4) at (b) (4) at (b) (4) at (b) (4) at (b) (4) may have been present in the vaccine and placebo.

CLINICAL MATERIAL:

			Potency	
Vaccine	Lot Number-Fill Number	Dosage	(PFU/dose)	Package
Live rotavirus vaccine	1340A/C-Y560A	1.0 mL	4 x 10 ⁷	Code-labeled vial kept at
Placebo	1341/C-Y561	1.0 mL	0	(b) (4) Code-labeled vial kept at (b) (4)

DIAGNOSIS/INCLUSION CRITERIA: Healthy infants, 2 to 6 months of age who had no known or suspected impairment of immunologic function; no prior administration of any rotavirus vaccine; no fever (defined as a rectal temperature of ≥100.4°F) at the time of immunization; no history of chronic diarrhea or failure to thrive; no clinical evidence of active gastrointestinal disease; no other vaccines given within (+/-) 14 days of any dose of vaccine; no condition that, in the opinion of the investigator, could have interfered with the evaluation of the study objectives; and no infant who resided in a household with an immunocompromised individual.

EVALUATION CRITERIA: <u>Efficacy</u>: The case definition for rotavirus gastroenteritis was that a subject must have met both of the following criteria: $(1) \ge 3$ watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting. (2) Rotavirus must have been identified in a stool specimen taken within 14 days of the onset of symptoms. <u>Immunogenicity</u>: Serum samples, taken Predose 1 and Postdose 3, were tested by enzyme immunoassay (EIA) for serum neutralizing antibody (SNA) against G1, G2, G3, P1a, P1G1, G6, and P7. Serum was also tested for anti-rotavirus IgA and IgG. Stool samples, taken Predose 1 and Postdose 3, were tested to record any adverse experiences that occurred within 14 days after any vaccination. Temperatures were recorded daily for 7 days after each administration of vaccine/placebo. Stool samples for viral shedding were obtained from all participants between Day 3 and Day 5 after Dose 1. In addition, the Philadelphia study site collected stool samples for vaccine viral shedding 1 to 2, 3 to 5, 7 to 9, and ~15 days following each dose.

STATISTICAL PLANNING AND ANALYSIS:

Efficacy: The primary efficacy hypothesis that the quadrivalent rotavirus vaccine provides efficacy against rotavirus disease throughout one rotavirus season was tested using an exact conditional procedure. The primary hypothesis in the protocol refers to 80% efficacy, which is the expected efficacy that was used for power and sample size calculations; however, the primary hypothesis was tested for vaccine efficacy >0.0% relative to placebo, as noted in the Data Analysis Plan (DAP). A point estimate and exact two-sided 95% confidence interval for vaccine efficacy were also calculated. In order for the quadrivalent rotavirus vaccine to be declared efficacious (i.e., in order to reject the null hypothesis), the lower bound on the confidence interval for vaccine efficacy had to exceed 0%. If there were 160 evaluable infants per group, and assuming that the true incidence of disease in the placebo group would be 10% and that the vaccine would be 80% efficacious in the prevention of rotavirus disease, there would be 80% power to reject the primary null hypothesis. One hundred eighty (180) evaluable infants per group would provide 80% power with an attack rate as low as 9% in the placebo group.

BC3418.DOC VERSION 18.0 APPROVED

Restricted Confidential - Limited Access

09-Dec-2003

V260 G1 G2 Reassortant Rotavirus Vaccine Live (Human-Bovine) Oral Rotavirus Gastroenteritis

CSR SYNOPSIS (CONT.) Protocol 003

-2-

SUBJECT ACCOUNTING:							
		Rotavirus (G1, G2) Vaccine					
	1.0 mL - No Buffer (Group 1)	1.0 mL - 1x Buffer (Group 3)	2.5 mL – 1x Buffer (Group 5)	1.0 mL – Conc. Buffer (Group 7)	(Groups 2, 4, 6, and 8 Combined)		
ENTERED: Total	142	150	147	142	150		
Male (age range-weeks)	64 (8 to 21)	74 (8 to 21)	76 (6 to 21)	77 (8 to 21)	79 (8 to 21)		
Female (age range—weeks)	78 (6 to 21)	76 (8 to 21)	71 (7 to 21)	65 (8 to 21)	71 (8 to 21)		
COMPLETED:	136	138	137	132	138		
DISCONTINUED: Total	6	12	10	10	12		
Clinical adverse experience	0	1	0	2	2		
Refused further participation	3	6	6	5	6		
Lost to follow-up	3	- 5	4	3	4		

DOSAGE/FORMULATION NOS.: Regimen: Three (3) doses of the clinical material were administered to each subject orally. The volume of administration was either 1.0 mL or 2.5 mL, depending upon the subject's group assignment. Each dose was provided under the following schedule: Dose 1, given on Day 0.

Dose 2, given between Days 42 and 56.

Dose 3, given between Days 84 and 98.

Group	Prefeeding	Vaccine Vol (mL)	Buffer/Stabilizer	PFU/Dose
1	Yes	1.0	None	1x 10 ⁷ PFU
2†	Yes	1.0	None	0
3	No	1.0	1x	1x 10 ⁷ PFU
4 [†]	No	1.0	1x	0
5	No	2.5	1x	1x 10 ⁷ PFU
6†	No	2.5	1x	0
7	No	1.0	Concentrate	1x 10 ⁷ PFU
8†	No	1.0	Concentrate	0
[†] Placebo.				

CLINICAL MATERIAL: G1 and G2 human-bovine reassortant rotavirus vaccine, a live virus vaccine, Lots No. 1507/W-D152, 1493/W-C971, 1494/W-C972, and 1495/W-C973. The vaccine contained serotypes G1 and G2, each with an estimated final titer of 5 x 10⁶ PFU/reassortant or a total of 1x10⁷ PFU G1 and G2 human-bovine rotavirus reassortant vaccine per dose, in (b) (4) Medium (b) (4) Placebo represented buffer alone; i.e., without rotavirus vaccine, Lots No. 1506/W-D151, 1489/W-C967, 1490/W-C968, and 1491/W-C969.

Restricted Confidential – Limited Access

10-Sep-2003

CLINICAL STUDY REPORT I. SYNOPSIS

V260

G4 Human-Bovine Reassortant Rotavirus Vaccine, Oral Rotavirus gastroenteritis

PROTOCOL TITLE/NO .: Safety and Tolerability of Oral, Live	G4 Human-Bovine	#004				
Reassortant Rotavirus Vaccine in Healthy Adults and Healthy Infants						
INVESTIGATOR(S)/STUDY CENTER(S): Multicenter (02) U.S.						
PRIMARY THERAPY PERIOD: 19-Mar-1998 to 07-Jul-1998	CLINICAL PHASE:	IIb				
(last dose of therapy).						
Study completed: 18-Aug-1998.						
Clinical Case Report Form and Laboratory Data In-House Cut-off	Clinical Case Report Form and Laboratory Data In-House Cut-off					
Date: 10-Sep-1999.						
DURATION OF TREATMENT: Single dose/42-day follow-up.						
OBJECTIVE(S): To accord that the G4 reassortant retaying version i	a generally safe and wall to	laratad				

OBJECTIVE(S): To assess that the G4-reassortant rotavirus vaccine is generally safe and well tolerated, in order to include it in a multivalent oral live rotavirus vaccine.

STUDY DESIGN: Double-blinded, placebo-controlled randomized study organized in 2 stages. Stage 1 was conducted in healthy adults; Stage 2 was conducted in healthy infants, after subjects from Stage 1 had been followed 14 days without any vaccine-related serious adverse experiences. Within each stage, subjects were randomized between vaccine and placebo groups at a ratio of 2:1.

SUBJECT ACCOUNTING:

	Adults (Age Bange in Years)			Infants (Age Range in Weeks)			
A	Rotavirus	<u> </u>		Rotavirus (G4 Vaccine)			
	(G4 Vaccine)	Placebo	Total	Vaccine	Placebo	Total	
ENTERED: Total	10	5	15	47	23	70	
Male (age range)	6 (26 to 53)	3 (23 to 30)	9 (23 to 53)	25 (8 to 21)	13 (9 to 21)	38 (8 to 21)	
Female (age range)	4 (27 to 54)	2 (28 to 32)	6 (27 to 54)	22 (9 to 21)	10 (8 to 21)	32 (8 to 21)	
COMPLETED:	10	5	15	46	22	68	
DISCONTINUED: Total	0	0	0	1	1	2	
Clinical adverse experience	0	0	0	0	0	0	
Deviation from protocol	0	0	0	0	0	0	
Refused further participation	0	0	0	0	0	0	
Lost to follow-up	0	0	0	1	1	2	

DOSAGE/FORMULATION NOS.:

<u>Regimen</u>: A single, 1-mL dose of clinical material, vaccine or placebo, was administered orally to each subject on Day 0. The vaccine was given approximately one-half hour after the administration of a buffering agent.

Clinical Trial Material: The vaccine	contained G4 human-b	ovine reasso	rtant rotavir	us with an es	stimated
final titer of 10 ⁷ plaque-forming v	mits (PFU) in a 1-mI	dose. The	e vaccine c	omposition i	ncluded
(b) (4) Medium (b) (4) at	(b) (4)	at	(b) (4)	at
(b) (4) and sucrose	(b) (4)	, Lot No.	V260-OSO	-001-D001.	Trace
components of fetal bovine serum	may also have been	present in t	the vaccine	. The place	bo was
composed of (b) (4) Medium	(b) (4)	at (b) (4)	at (b) (4), and
Sucrose (b) (4)	, Lot No. 1506/W-D	51.			

01-Apr-2004 R 17-Dec-2004

CSR SYNOPSIS (CONT.) Protocol 007

V260 Rotavirus Vaccine, Live, Oral, Pentavalent -2-

DOSAGE/FORMULATION NOS.:

Regimen: Three (3) doses of the clinical material were administered to each subject orally. The volume of each vaccination was 2.0 mL of vaccine or placebo. Vaccination 1 was to be administered on Day 1, Vaccination 2 was to be administered 28 to 70 days after Vaccination 1, and Vaccination 3 was to be administered 28 to 70 days after Vaccination 2.

Clinical Material: RotaTeq[™] at expiry potency (Lot Nos. V260 VAO 019Q001 and V260 VAO 019Q002) contained approximately ^(b) ^(d) mg of sucrose, approximately ^(b) (b) ng of sodium citrate, approximately ^(b) (d) mg of sodium phosphate, ^(b) mL of tissue culture medium, and no greater than ^(b) ^(d) mg of polysorbate-80, and human-bovine rotavirus reassortants G1, G2, G3, G4, and P1 with an estimated final aggregate potency of ~1.1 x10⁷ infectious units (IU)/dose in approximately 2.0 mL of buffer/stabilizer. Theoretical calculation of ^(b) ^(d) (d) material ^(b) ^(d) was ^(b) µg/dose. Trace components of fetal bovine serum may have also been present.

The placebo (Lot No. PV260 VAO 009A009) was approximately 2.0 mL per dose that contained approximately and of sucrose, approximately approxima

DIAGNOSIS/INCLUSION CRITERIA: Healthy infants, 6 through 12 weeks of age, who had no known history of congenital abdominal disorders, intussusception, or abdominal surgery; no known or suspected impairment of immunological function; no known hypersensitivity to any component of the rotavirus vaccine; no prior receipt of any rotavirus vaccine; no fever, with a rectal temperature ≥38.1°C (≥100.5°F) at the time of immunization; no history of known prior rotavirus disease, chronic diarrhea, or failure to thrive; no clinical evidence of active gastrointestinal illness. (Note that infants with gastroesophageal reflux disease [GERD] were permitted to participate in the study as long as the GERD was well controlled with or without medication.); no receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 2 weeks prior to vaccination; did not reside in a household with an immunocompromised person, no prior receipt of a blood transfusion or blood products, including immunoglobulins; no receipt of oral poliovirus vaccine (OPV) during the course of the study or within 42 days prior to the first dose of vaccine/placebo; any infant who could not be adequately followed for safety by telephone or home visit; and no condition, which, in the opinion of the investigator, may have interfered with the evaluation of the study objectives.

EVALUATION CRITERIA:

- Efficacy: The case definition for rotavirus gastroenteritis required subjects to meet both of the following criteria: (1) 3 or more watery or looser-than-normal stools within a 24-hour period and/or forceful vomiting, and (2) Rotavirus detected by enzyme immunoassay (EIA) in a stool specimen taken within 14 days after the onset of symptoms. All rotavirus-positive stools were evaluated for serotype identification by polymerase chain reaction (PCR). Only naturally-occurring rotavirus AGEs caused by the human rotavirus G- serotypes in the vaccine were included in the primary analysis.
- **Immunogenicity:** In a subset of approximately 175 subjects, antibody responses to the vaccine were evaluated by several assays. Serum samples were collected before Dose 1 and approximately 42 days after Dose 3. Serum was tested by modified enzyme-linked immunosorbent assay (ELISA) for serum neutralizing antibodies (SNA) against the rotavirus serotypes contained within the vaccine (G1, G2, G3, G4, P1, and WC3 (the WC3 serotype is also characterized as G6 and P7[5] throughout this document)). Serum anti-rotavirus IgA was also evaluated.
- Safety: The subjects' parent/legal guardians were asked to record any adverse experiences that occurred within 42 days following any vaccination. The subjects' parent/legal guardians were instructed to record daily for the first 7 days following vaccination the subject's temperature, behavioral changes, and the number of episodes of vomiting and/or diarrhea.

21-Dec-2004

E. <u>STUDY DESIGN</u> (CONT.)

(WPS&E) department of Merck Research Laboratories (MRL) will also maintain a copy of the unblinded allocation schedule to assist with emergency unblinding, if needed.

Description of RotaTeq[™]: RotaTeq[™] will be supplied at a potency within the range of the final marketed release potencies, in the final formulation, and in the final container. Placebo will be supplied in an identical container. The estimated final volume/dose of RotaTeq[™] will be ~2 mL, with a potency release range between IU/reassortant/dose and (b) (4) (b) (4) IU/reassortant/dose, IU/dose. The formulation in which Rota TeaTM is suspended contains $\binom{(b)}{2}$ g sucrose, (b) (4) citrate, (b) (4) phosphate $\binom{10}{4}$ mL tissue culture medium, and no greater than (b) (4) mg polysorbate 80. (b)(4)is present in a vaccine dose. Trace components of fetal bovine serum may also be present.

Description of the Placebo: Placebo is ~ 2 -mL dose that contains (4) g sucrose, (b) (4) citrate, (b) (4) phosphate, (b) mL tissue culture medium, and no greater than (b) mg polysorbate 80.

b. Special Handling Requirements

Once labeled, RotaTeqTM will be indistinguishable from placebo. Both the vaccine and placebo used in this study will be provided in 5.5-mL labeled oral dosing tubes containing ~ 2 mL of product. Each RotaTeqTM/placebo shipment will include a temperature monitoring device ((b) (4)) or similar device) to record vaccine temperature during shipping. The recorders must be removed and deactivated **immediately** upon arrival of the shipment. The temperature-monitoring device must be returned to the SPONSOR. See Appendix 2 for detailed instructions.

The RotaTeqTM/placebo should be placed in the refrigerator at 2 to 8°C immediately after arrival, and should be stored refrigerated until needed for administration. A refrigerator temperature log, recording the daily minimum and maximum temperatures, must be maintained at the site. The log will be reviewed throughout the course of the study by the site field monitors. Refrigerator temperatures should be from 2 to 8°C for RotaTeqTM/placebo storage. Should the refrigerator temperature reach above 8°C [46.4°F] or $(b)^{(4)}$ the SPONSOR (MPC) should be notified immediately and the RotaTeqTM/placebo should not be used.

RotaTeqTM/placebo should be administered within 30 minutes of being removed from refrigeration. Study personnel should contact their MPC if this time limit is exceeded.

20-Dec-2002

E. <u>STUDY DESIGN</u> (CONT.)

Description of RotaTeqTM: RotaTeqTM will be supplied at a potency within the range of the final marketed release potencies, in the final formulation, and in the final container. Placebo will be supplied in an identical container. The estimated final volume/dose of RotaTeqTM will be ~2 mL, with a potency release range between (b) (4) IU/reassortant/dose and (b) (4) IU/reassortant/dose, (b) (4) IU/reassortant/dose. The formulation in which RotaTeqTM is suspended contains (c) g sucrose, (b) (4) citrate, (b) (4) phosphate, (b) (4) is present in a vaccine dose. Trace components of fetal bovine serum may also be present.

Description of the Placebo: Placebo is ~ 2 -mL dose that contains $\begin{bmatrix} D \\ A \end{bmatrix}$ g sucrose, $\begin{bmatrix} b & (4) \\ (4) \end{bmatrix}$ citrate, $\begin{bmatrix} (5) & (4) \\ (4) \end{bmatrix}$ phosphate, $\begin{bmatrix} (b) \\ (4) \end{bmatrix}$ mL tissue culture medium, $\begin{bmatrix} (a) & (b) \\ (4) \end{bmatrix}$ mg polysorbate 80.

b. Special Handling Requirements

Once labeled, RotaTeqTM will be indistinguishable from placebo. Both the vaccine and placebo used in this study will be provided in 5.5-mL labeled oral dosing tubes containing ~2 mL of product. Each RotaTeqTM/placebo shipment will include a temperature monitoring device (b) (4) or similar device) to record vaccine temperature during shipping. The recorders must be removed and deactivated **immediately** upon arrival of the shipment. The temperature-monitoring device must be returned to the SPONSOR. See Appendix 2 for detailed instructions.

The RotaTeqTM/placebo should be placed in the refrigerator at 2 to 8°C immediately after arrival, and should be stored refrigerated until needed for administration. A refrigerator temperature log, recording the daily minimum and maximum temperatures, must be maintained at the site. The log will be reviewed throughout the course of the study by the site field monitors. Refrigerator temperatures should be from 2 to 8°C for RotaTeqTM/placebo storage. Should the refrigerator temperature reach above 8°C [46.4°F] or $\binom{10}{4}$ the SPONSOR (MPC) should be notified immediately and the RotaTeqTM/placebo should not be used.

RotaTeqTM/placebo should be administered within 30 minutes of being removed from refrigeration. Study personnel should contact their MPC if this time limit is exceeded.